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Sphingolipids are important signaling molecules regulating cell growth, cell death and differentiation, 
thus making them important molecules in determining the fate of a cell and in the pathogenesis of 
chronic illnesses. The sphingolipid signaling pathway can be initiated by reactive oxygen species 
(ROS) and inflammatory molecules, both of which are believed to be upregulated in a state of 
obesity. The hypothesis tested in this dissertation is that due to the inflammatory state of obese 
animals, the sphingolipid pathway is altered, shifting the balance of pro- and anti-apoptotic proteins 
and contributing to the pathogenesis of diseases associated with an obese state. The specific aims 
were to compare, 1) key sphingolipid signaling enzymes; 2) levels of sphingolipid signaling 
molecules and 3) pro and anti-apoptotic protein levels, in hepatic and colonic tissues procured from 
lean and obese animals.  
 
Obese animals are susceptible to various diseases, including colon cancer and hepatic steatosis. To 
assess the effect of obesity on sphingolipid signaling, and to provide insight as to the pathogenesis of 
diseases in a state of obesity, liver and colon tissues from Zucker obese female rats (fa/fa) were 
compared to tissues from their lean counterparts (Fa/fa or Fa/Fa Zucker rats). Enzyme analyses 
included an assay of sphingomyelinase (SMase) activity and quantification of ceramidase and 
sphingosine kinase-1 (SK1) protein expression by western blot. Also, sphingomyelin (SM), ceramide, 
ceramide-1 phosphate (C1P), sphingosine and sphingosine-1-phosphate (S1P) levels were determined 
by high-performance liquid chromatography (HPLC) -tandem mass spectroscopy (MS). 
Representative apoptotic proteins, Bax and Bcl-2 were quantified by western blot.  
Obese liver demonstrates hepatic steatosis in the Zucker animal model. Among the major 
differences noted between obese and lean liver were significantly upregulated ceramidase, and 
downregulated SK1 and C1P levels (P<0.05), as well as a difference in ceramide and SM species 
composition. Bax was overexpressed while Bcl-2 level was lower in obese compared to lean liver 
(P<0.05). Taken together, the results indicate a shift toward higher apoptotic signaling in obese liver 
tissue and correspond with the diseased state of the steatotic liver.  
Analysis of the sphingolipid pathway in colon revealed upregulation of ceramidase and 
downregulation of SK1 (P<0.05), similar to liver tissue. C1P levels were lower (P<0.05) but no 
changes were observed for ceramide, SM or sphingosine levels. A trend toward higher SMase activity 
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in obese colon was observed. Bax was overexpressed in obese colon tissue (P< 0.05), while Bcl-2 
results were inconclusive.  
The liver expressed lower level of molecules associated with sphingolipid signaling than the 
colons. This study is first to demonstrate tissue-specific differences in the sphingolipid signaling 
pathway, regardless of genotype. Nevertheless, overall the genotype of Zucker model was found to be 
a factor altering the expression levels of various sphingolipid enzymes and metabolites in both colon 
and liver. The findings of the present research provide incentive to further understand the role and 
modulation of sphingolipid signaling pathway in causation and prevention of chronic diseases 
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The objective of this thesis was to investigate the differences in the sphingolipid signaling pathway 
between lean and obese animals in liver and colon tissue for the purpose of investigating whether the 
sphingolipid pathway may be a contributing factor to the pathogenesis of hepatic steatosis and colon 
cancer in obese animals.  
 
Sphingolipids are important signaling molecules regulating cell growth, cell death and differentiation, 
making them important molecules for determining the fate of cells. The sphingolipid signaling 
pathway can be initiated by reactive oxygen species (ROS) and inflammatory molecules. As obese 
animals are in a constant state of inflammation and are susceptible to various diseases, specifically 
hepatic steatosis and colon cancer, it is valuable to see if the sphingolipid signaling pathway is altered 
in this state and contributing to disease susceptibility. Any alteration of the sphingolipid pathway will 
result in a change in the balance between pro-apoptotic and anti-apoptotic proteins. The proteins that 
are involved in the sphingolipid signaling pathway, as well as key pro- and anti-apoptotic proteins, 
were compared in lean versus obese colon and liver. This provides insight into changes that occur to 
the sphingolipid pathway in a state of obesity and how these changes may contribute to the 
pathogenesis of various diseases.   
 
The specific aims were to: 
1) Analyze key sphingolipid signaling enzymes in lean versus obese animals. 
2) Compare levels of sphingolipid signaling molecules in lean versus obese animals. 
3) Analyze pro and anti-apoptotic protein levels in lean and obese animals. 
 
Hypothesis: Due to the inflammatory state of obese animals, the sphingolipid pathway is altered, thus 
shifting the balance of pro- and antiapoptotic proteins and contributing to the pathogenesis of disease 
in an obese state. 
 
The background information in the following sections describes the sphingolipid signaling pathway, 





1.2 Sphingomyelin and its Signaling Cascade 
  Sphingomyelin Pathway 
Sphingolipids have emerged as important signaling molecules mediating cell proliferation, 
differentiation and apoptosis. The sphingomyelin signaling cascade, in particular, has received a lot of 
attention for its role in the pathology of several human diseases, including Alzheimer’s disease, 
atherosclerosis, and a number of cancers. Sphingomyelin (SM) is a main phospholipid component of 
animal cell membranes. It is especially concentrated in membranous myelin sheaths of myelinated 
nerves. SM consists of sphingosine (a long, unsaturated fatty acid chain) attached to a fatty acid and 
choline (a polar head group) (Fig.1). The ceramide backbone of sphingolipids is generated in the 
endoplasmic reticulum, while the polar head groups are added in the golgi apparatus. 
  
                     















Most sphingolipids reside in membrane bilayers and are concentrated in lipid rafts (Levade, 2001). 
Due to its location, sphingomyelin was long believed to serve only structural roles, providing a barrier 
to the extracellular environment (Kolesnick, 2002). More recent studies have demonstrated the 
existence of a sphingomyelin signaling cascade, initiated when sphingomyelin becomes hydrolyzed 
into secondary messengers. Three main secondary messengers of sphingomyelin are now recognized: 
ceramide, sphingosine, and sphingosine-1-phosphate (S1P), though there are many other sphingolipid 
derivatives. The various conversions between molecules in the sphingolipid pathway are illustrated 
below (Fig. 2). 
 
The pathway is initiated by the hydrolysis of the phosphodiester bond of sphingomyelin via the 
enzyme, sphingomyelinase (SMase).  The action of SMase on sphingomyelin releases ceramide, a 
pro-apoptotic signaling molecule (discussed in section 1.3). Alternatively, ceramides can be formed 
by de novo synthesis, whereby the amino acid serine is condensed sequentially with two fatty acids 
by the actions of serine palmitoyl transferase and ceramide synthase. Ceramides can be converted 
back to SM by the transfer of phosporylcholine from the phospholipid phosphatidylcholine to 
ceramide via the enzyme SM synthase. 
Once generated, ceramide may accumulate or may be transformed to other metabolites, including 
sphingosine.  Ceramide is converted to sphingosine when it is deacetylated by ceramidase. Ceramide 
can also be phosphorylated to ceramide 1 phosphate (C1P) by the action of ceramide kinase (CerK). 
C1P can readily be converted back to ceramide by the action of phosphatidic acid phosphohydralase. 
Sphingosine can be converted back to ceramide via the enzyme ceramide synthase or can be further 
converted to the proliferative molecule, S1P, through phosphorylation via sphingosine kinase. This 
phosphorylation is easily reversible via the enzyme sphingosine-1-phosphate phosphatase, which 
dephosphorylates S1P back to sphingosine. 
The metabolites that result from the action of sphingomyelinase play varied roles in cell signaling 
(discussed in Section 1.3). The relative levels of these molecules as well as the enzymes that convert 
them may be important indicators of the fate of cells in a given tissue type. A deeper knowledge of 






































Figure 2: Schematic of sphingomyelin signaling cascade, showing the conversions between apoptotic 






  Sphingomyelinase 
Sphingomyelinase, with its phospholipase C activity, initiates the sphingomyelin signaling pathway 
by hydrolyzing the phosphodiester bond of SM. Three distinct isoforms of SMase have been 
identified based on their pH optima: neutral SMase, acid SMase and alkaline SMase (Kolesnick, 
2002). The pH affects the on-off rate of the substrate to SMase, rather than the catalytic activity of the 
enzyme (Schissel et al., 1998). Neutral SMase (pH optimum 7.4) and acid SMase (pH optimum 4.5-
5.0) are similar in structure and function and are present in all cell types (Kolesnick, 2002), while 
alkaline SMase (optimal pH 9-9.5) is structurally distinct and is found only in the gastrointestinal 
tract (Cheng et al., 2002).  
 Alkaline SMase, discovered in 1969 by Nilsson, may be important in the digestion of dietary SM 
(Cheng et al., 2004). This belief is due to studies that indicate that dietary SM is not hydrolyzed by 
pancreatic juice, and SM digestion occurs where alkaline SMase levels are abundant – in the middle 
and lower small intestine (Cheng et al., 2002). This enzyme may play a protective role in colon 
carcinogenesis, as feeding mice with ceramide or SM reduced the number of aberrant crypt foci 
(Schmelz, et al., 1997; Schmelz et al., 1999). Furthermore, in human adenoma and colonic carcinoma, 
the activities of alkaline sphingomyelinase are reduced by 50% and 75%, respectively (Herervig et al. 
1996). 
Acid sphingomyelinase was long believed to be exclusively a lysosomal enzyme (Kolesnick, 
2002). However, more recent studies have isolated acid SMase from secretory vesicles near plasma 
membranes (Grassme et al., 2001), and an acidic sphingomyelinase has been found to be secreted 
extracellularly from macrophages, fibroblasts and endothelial cells (Schissel et al., 2006; Marathe et 
al., 1998). Acidic SMase has also been observed in caveolae, microdomains rich in SM (Liu et al., 
1995). In acidic SMase knockout mice, residual SMase activity remains (Horinouchi et al., 1995), 
demonstrating the existence of one or more distinct genes that must encode such enzymes.  Neutral 
sphingomyelinase is indeed genetically distinct from acidic sphingomyelinase (Chatterjee, 1999). It is 
magnesium dependent and is considered a membrane-bound enzyme (Chatterjee, 1993).  
Neutral and acidic SMases are activated by a wide range of stressors to increase cellular ceramide 





Fas ligand, as well as UV-exposure, free fatty acids, radiation and oxidative stress (Woodock, 2006; 
Ogretmen, 2006; Kolesnick, 2002). This ability of sphingomyelinase to convert stress signals into 
biochemical messengers is what makes it an important and interesting enzyme to be studied in many 
disease processes. 
 Ceramidase 
Ceramidase (N-acylsphingosine deacylase) further participates in the modulation of the signal 
transduction pathway. It cleaves the N-acyl linkage of ceramide to produce sphingosine and a fatty 
acid (Tani et al., 1998).  Ceramidase exists in mammals as a 55kDa precursor protein that can be 
cleaved to a mature 40kDa protein. Like sphingomyelinase, this enzyme can also be classified 
according to its optimal pH into acid and neutral and alkaline isoforms, coded for by different genes 
(Kolesnick, 2002; Xu et al., 2006). 
Acid ceramidase is synthesized as a precursor polypeptide that is proteolytically processed into 
alpha and beta subunits (Park et al., 2006). With an optimal pH of 4.0-5.0, acid ceramidase is found 
mainly in lysosymes and cell membranes, though a portion of the enzyme may be secreted and other 
subcellular locations may exist (Park et al., 2006). A recently identified alkaline, ceramidase (Xu et 
al., 2006), has been found localized to the golgi complex. Overexpression of this enzyme can lead to 
sphingosine accumulation within cells. Neutral ceramidase is found in kidney and intestinal cells 
(Olsson et al., 2004). It has been postulated that this enzyme is necessary in the gastrointestinal tract 
to metabolize dietary and brush border ceramide (Olsson et al., 2004).  
 
 Sphingosine Kinase 
Sphingosine kinase is responsible for the phosphorylation of sphingosine, yielding the sphingolipid 
metabolite, S1P. Two distinct isoforms of sphingosine kinase, SK1 and SK2, have been identified and 
cloned (Kahoma et al., 1998; Liu et al., 2000). SK1 can be stimulated by external stimuli, particularly 
growth and survival factors. Recognized inducers of SK1 include platelet-derived growth factor 
(PDGF) and TNF-α, among others (Olivera et al., 1999; Huang et al., 2007). It is well established that 
S1P produced by SK1 inhibits apoptosis and promotes cell growth and proliferation (reviewed in 





Much less is known about SK2, though it appears to have a distinct physiological role from SK1. 
SIP derived from SK2 has been implicated in enhanced apoptosis and suppressed growth, which 
contrasts the proliferative effects of SK1-derived S1P (Liu et al., 2003; Igarashi et al., 2003). While 
the SKs appear to have distinct functions, the two enzymes have highly similar amino acid sequences 
and possess five evolutionarily conserved domains. SK2 differs from SK1 only in its amino terminus 
and central region (Maceyka et al., 2005).  
One possible explanation for the differential effects of these isoenzymes is that S1P may have 
distinct functions depending on which compartment of the cell it is produced in, and SK1 and SK2 
have been found to be located or translocated to different areas within the cell. SK1 has been shown 
to be predominantly cytosolic and can be translocated to the plasma membrane by growth factors 
(Speigel et al., 2003). S1P produced by the translocation of SK1 can activate the cell surface receptor 
G protein-coupled receptors, also known as the Edg receptors (reviewed in Young et al., 2006). SK2, 
on the other hand, is found in low levels in the cytosol and has been found to be mainly localized to 
the plasma membrane and endoplasmic reticulum (Maceyka et al., 2005). S1P made by SK2 does not 
transactivate the Edg receptors. Treatment with an inhibitor of G-coupled S1P receptor does not 
interfere with the ability of SK2 to induce apoptosis (Liu et al., 2003). Despite the opposing 
implications of S1P produced by these two different isozymes, SK1 is the more predominant isozyme 
and, therefore, S1P is regarded as a promoter of cell growth and differentiation.  
 
1.3 Sphingolipids in Cell Death/Survival 
 Altered Bcl-2 Proteins and Apoptotic Signaling by Ceramide and Sphingosine 
The primary products of sphingomyelinase, ceramide and sphingosine, mediate and trigger apoptosis, 
while S1P is considered to be a survival molecule, promoting proliferation. Ceramide plays a role in 
apoptotic signaling by altering the biophysical characteristics of cellular membranes. The turnover of 
sphingomyelin at the plasma membrane results in sphingolipid-rich domains known as lipid rafts, 
where there is a clustering of receptors and signaling molecules (Ohanian and Ohanian, 2001). In this 
way, ceramide influences membrane receptor signaling.  
  
The role of ceramide in apoptosis is not fully defined, though some preliminary associations have 
been determined. Cellular targets for ceramide include cathepsin D, ceramide-activated protein 
 
 8 
phosphatases (CAPPs), and the stress activated protein kinases (SAPKs) among others. Binding of 
ceramide to cathepsin D in vitro or in endosomes prompts autolytic cleavage of cathepsin to its active 
form (Kolesnick, 2002). While the function of cathepsin D is not clearly defined as of yet, ceramide-
induced activation of cathepsin D has been shown to mediate activation of Bid, a pro-apoptotic Bcl-2 
family member (Heinrich et al., 2004).  In studies where cathepsin D was inhibited in apoptotic 
stimulated cells, cells were able to survive or delay death (Johansson et al., 2003; Diess et al., 1996). 
Both protein phosphatase 1 (PP1) and protein phosphatase 2a (PP2a) are serine/threonine CAPPS 
that will induce growth arrest or apoptosis in response to a rise in ceramide levels (Kolesnick, 2002). 
There are several targets for CAPPs, including protein kinase C alpha (PKCα), Akt/protein kinase B 
(PKB) and Bax. PKC is involved in signal transduction, and growth/metabolic regulation (Chalfant et 
al., 2006). PKC has been implicated as an anti-apoptotic molecule and it has been proposed that 
inactivation of PKCα is important in inducing apoptosis (Gamard et al., 1996). Studies performed on 
Molt-4 Leukemia cells indicate that PP2a inactivates PKC by removing critical phosphates, thus 
allowing the induction of apoptosis (Chalfant and Hannun, 2006). CAPP also inactivates Akt/PKB by 
dephosphorylation. Inactivated Akt/PKB is responsible for phosphorylating substrates such as 
caspase 9, which has been proposed as a necessary step in apoptosis (Cardone et al., 1998).  
PP2a has more recently been shown to activate the pro-apoptotic Bcl-2 family member, Bax, 
through dephosphorylation. This dephosphorylation of Bax by PP2a has been shown to be mediated 
by ceramide and leads to subsequent cytochrome c release, caspase activation, and apoptosis (Xin et 
al., 2006). Ceramide has also been implicated in upregulating other pro-apoptotic Bcl-2 family 
members, including Bid and Bad, while downregulating antiapoptotic Bcl-2 and Bcl-XL (Zhang et al., 
2006; Chalfant and Spiegel, 2005). Bcl-2 and Bcl-XL prevent apoptosis by binding to Apaf-1, 
preventing Apaf-1 activation of caspase 9 (Hu et al., 1998).  Furthermore, heterodimerization of Bcl-2 
to Bax prevents apoptosis (Vincenzo et al., 1998). Thus the balance between these pro- and 
antiapoptotic proteins is an important determinant in the fate of the cell, while the ability of ceramide 
to alter this balance may be fundamental in its apoptotic signaling ability. 
More recent studies have shown ceramide to activate a mixed lineage kinase (MLK). MLK lies 
upstream of the SAPK pathway, and ceramide has proven to activate this kinase both in vitro and in 
vivo, thereby activating pro-apoptotic Jun kinase (JNK) (Sathyanarayana et al., 2002). Though much 
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is known about the role of ceramides in apoptosis, research it still ongoing. Since ceramides act on a 
number of other targets, there could be many additional ways by which ceramides affect apoptosis.  
Sphingosine’s role in apoptosis is less established. Though sphingosine activates some of the same 
pathways as ceramide, it can positively and negatively affect kinase activities, and unlike ceramide, is 
not confined to membranes (Woodcock, 2006). Sphingosine has been demonstrated to inhibit PKC 
(Smith et al., 2000) and has been implicated in activating the SAPK/JNK pathway (Ruvolo et al., 
2003). For these reasons, sphingosine is considered a pro-apoptotic molecule.  
The apoptotic actions of ceramide are depicted in the following figure (Fig.3). 
 
 
Figure 3: Apoptotic pathways of ceramide.  
Ceramide can mediate apoptosis through: (1) the stress activated protein kinase (SAPKs), which activate pro-
apoptotic Jun-kinase (JNK); (2) cleavage of cathepsin D to activate pro-apoptotic Bid; (3) ceramide-activated 






1.3.2 Cell Survival Signaling by S1P and C1P 
In contrast to ceramide and sphingosine, S1P has been implicated as a cell survival molecule. The 
metabolic conversion from ceramide/sphingosine to S1P is, therefore, capable of switching cells from 
an apoptotic state to a proliferative state. S1P has been found as an important signal in cell 
proliferation, induced by potent mitogens (Olivera and Spiegel, 1993). It has been shown to not only 
stimulate DNA synthesis, but also to cause an increase in cell division (Desai et el, 1992).  
Furthermore, S1P promotes cell survival and suppresses ceramide-mediated apoptosis (Cuvillier et 
al., 1996).  
It has been established that cellular targets for S1P are the cell surface Edg family of G-protein 
coupled receptors (Lee et al., reviewed in Young et al., 2006). So far Edg 1, 3, 5, and 8 have been 
identified as receptors that bind S1P with high affinity and specificity (reviewed in Young et al., 
2006). However, the biological functions of these receptors remain poorly understood. Preliminary 
work shows a possible role of these differentially expressed receptors in cell migration (Wang et al., 
1999), though clearly this is an area for further research.  
The intracellular targets for S1P have not yet been unequivocally determined, however, several 
enzymes and pathways have been identified. S1P has been shown to inhibit acid SMase in 
macrophages, thereby blocking the sphingomyelinase from producing pro-apoptotic ceramide and 
promoting cell survival (Gomez-Munoz et al., 2003). S1P may also promote proliferation by 
activating the mitogen-activated protein kinases (MAPKs), Erk-1 and Erk-2 (Cuvillier et al., 1996), 
proteins responsible for regulating cell growth and differentiation. As well, S1P activates 
phospholipase D (Desai et al., 1992).  Phospholipase D and its product, phophatidic acid, are involved 
in enhancing cell proliferation and preventing cell cycle arrest (Foster and Xu, 2003).  S1P 
counteracts ceramide-mediated cell death by inhibiting the JNK/SAPK pathway (Cuvillier et al., 
1996).  
Like S1P, C1P is an anti-apoptotic molecule, though the pathways and metabolic targets of C1P are 
not well characterized. It was identified over a decade ago but its biological importance has only just 
begun to be elucidated and appreciated. C1P is formed via phosphorylation of ceramide by ceramide 
kinase (CerK). CerK is a relative of SK1 catalyzing the formation of ceramide to C1P (Siguira et al., 
2002). C1P was first described as a putative stimulator of cell proliferation and was shown to simulate 
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DNA synthesis in rat fibroblasts (Gomez-Munoz et al., 2005). C1P has been shown to block 
caspase3/caspase 9 pathway activation, thereby inhibiting apoptosis in macrophages (Gomez-Munoz 
et al., 2004). It has also been shown to upregulate BcL-XL, an antiapoptotic member of the Bcl-2 
family of proteins that is downregulated by ceramide (Gomez-Munoz et al., 2005). 
Similarly to S1P, C1P has been shown to inhibit acid SMase. This has been demonstrated in both 
macrophages and cell homogenates, thereby preventing ceramide accumulation and apoptosis 
(Gomez-Munoz at al, 2004). Receptors for C1P remain unknown and instead it is suggested that C1P 
interacts with its targets such as acid SMase directly (Gomez-Munez at al, 2004). Other targets for 
C1P include PP1 and PP2a. While ceramide activates these protein phosphatases, C1P has been 
shown to inhibit these proteins in vitro (Chalfant, 2004). Inhibition of phosphatases PP1 and PP2a has 
been associated with activation of the proliferative Erk-1/Erk-2 pathway, increasing DNA synthesis 
and cell division (Doughetry et al., 2005). While further studies need to be carried to confirm the 
effects of C1P on protein phosphatases in vivo, this coincides with the survival effect of C1P.  
It is clear that both C1P and S1P function distinctly to oppose pro-apoptotic ceramide signals. 
Since all the bioactive sphingolipids discussed are mutually convertible, the overall balance of these 
molecules is important. Future examination of the ceramide/sphingosine/S1P/C1P relationships, as 
well as the enzymes that produce and degrade these metabolites, should shed light on other cell 
death/survival pathways that are affected by this delicate balance.  
  
 
1.4 Obese State and Disease 
Obesity is a chronic disease characterized by an increase in body fat stores (Formiguera and Canton, 
2004). Due to its prevalence, obesity is currently the most common metabolic disease in the world 
(Formiguera et al., 2004).  The World Health Organization (WHO) has claimed it to be a world-wide 
epidemic of the 21st Century. Although obesity is considered a disease on its own and is directly 
related to mortality, part of its threat lies in the fact that it increases the risk for various other diseases, 
including cardiovascular disease, hypertension, dyslipidemia, type-2 diabetes and cancer, among 





The sphingolipid pathway becomes an important area of study in obesity since it may be altered in 
an obese state, thus affecting the cell proliferation/death balance and contributing to the increased 
pathogenesis of certain diseases. Research is limited in this area. The only study to date compares 
adipose tissue of lean and obese mice and showed an overall decrease in SM and ceramide in obese 
mice compared to lean, with an increase in sphingosine and neutral and acidic SMase. Plasma levels 
of obese mice showed increased levels of sphingomyelin, ceramide, sphingosine and S1P, 
contributing to the proinflammatory phenotype of the obese adipose tissue (Samad et al., 2006).  
 
 Obesity, Hepatic Steatosis and Sphingolipid Metabolism  
1.4.1.1 Biology of the Liver 
The liver is the largest internal organ by percent weight in the human body and has crucial functions, 
including cholesterol production, intermediary metabolism, hormone synthesis, bile and urea 
production and drug detoxification. The functional cells of the liver are eosinophilic cells referred to 
as hepatocytes.  
 
The liver is organized into structural units called lobules. Each lobule is centered around a terminal 
hepatic venule. Radiating from the central venule are plates of hepatocytes separated by wide vascular 
channels called sinusoids. Sinusoids carry blood from the terminal branches of the portal vein and 
hepatic artery, which bring nutrient rich blood from the gastrointestinal tract and oxygen rich-blood 
from the lungs, respectively (Young et al., 2000). Sinusoids thus allow blood to have intimate contact 
with hepatocytes, allowing for exchange of nutrients and metabolic products.  
 
1.4.1.2 Sphingolipid Metabolism and Hepatic Steatosis in Obesity  
 
Hepatic steatosis is a condition of the liver, defined as an excess of triglycerides in hepatocytes. This 
condition was long thought to be mainly a symptom of alcoholic liver disease. In recent years, 
however, steatosis has been found in the absence of alcohol abuse and led to the definition of a series 
of disorders ranging from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH). 




hyperlipidaemia (Raman and Allard, 2006).  Insulin resistance has emerged as the most common 
disorder associated with hepatic steatosis (Angulo, 2002). Obesity and insulin resistance result in 
increased release of free fatty acids from adipocytes due to the activity of a hormone sensitive lipase. 
The elevated plasma levels of free fatty acids result in a higher influx of free fatty acids to the liver. 
Free fatty acids taken up by hepatocytes are metabolized by three different pathways: oxidation to 
form ATP, esterification to produce triglycerides for storage or incorporation into VLDL particles. 
Defects or changes in these pathways, such as increased esterification, decreased oxidation or faulty 
VLDL secretion can lead to hepatic steatosis (Browning and Horton, 2002).  
 
Additionally, hepatic steatosis is linked to oxidative stress and inflammation (Chitturi and Farrell, 
2001). Oxidative stress resulting from mitochondrial fatty acids oxidation, adipocytokines, and NF-
kappaB-dependent inflammatory cytokine expression are all considered to be the potential factors 
leading to hepatocyte injury and inflammation in fatty liver disease (Duvnjak et al., 2007). Oxidative 
stress and inflammatory cytokines are known inducers of sphingomyelinase, activating the 
sphingolipid pathway. Despite this knowledge, there is limited research on hepatic steatosis and its 
affects on the sphingolipid signaling pathway.  In a recent study, sphingomyelin was found to be 
downregulated in livers of obese mice compared to their lean counterparts (Yetukuri et al., 2007). As 
well, in a study comparing obese women with fatty livers to obese women with normal livers, it was 
found that both SMase and ceramide were significantly higher in adipose tissue in the fatty liver 
group (Kolac et al., 2007). It is clear that fatty liver disease does affect the sphingolipid pathway, but 
this is a novel area of research lacking conclusive results.  It is therefore worthwhile to profile the 
sphingolipid pathway in this tissue, to clearly demonstrate how sphingolipid pathway is altered in an 
obese state/hepatic steatosis versus a normal lean state. 
 
 
 Obesity, Colon Cancer, and Sphingolipid Metabolism 
1.4.2.1 Biology of the Colon 
 The mammalian colon, or large intestine, functions to store waste, absorb water, maintain water 
balance in the body and absorb vitamins, such as vitamin K. The large intestine can be divided into 
four distinct concentric layers: the mucosa, the submucosa; the muscularis externa; and the 
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adventita/serosa. The mucosa is the innermost layer of the digestive tract. Next is the submucosa 
consisting of dense connective tissue and functioning to vascularize and innervate the colon. The 
muscularis externa consists of muscular layers necessary for propelling waste through the large 
intestine. The adventitial layer consists of epithelial layers and a thin connective layer forming a 
serous membrane. In terms of colon cancer development, it is the mucosa that becomes the most 
important layer to examine.  
 
The mucosa can be further divided into three layers: epithelium; lamina propria; and muscularis 
mucosa. A single layer of epithelial cells lines the entire surface of the mucosa. Beneath the 
epithelium lies the lamina propria, consisting of loose connective tissue. The epithelium protrudes 
down through the lamina propria in intestinal glands known as the crypts of Lieberkuhn (Young et al., 
2000). It is within these glands where loss of proliferation control is attributed to colon cancer. A thin 
layer of smooth muscle tissue referred to as the muscularis mucosa lies beneath the lamina propria 
and keeps the mucosal surface and glands in a state of gentle agitation to expel contents of glandular 
crypts and improve contact between the epithelium and the contents of the lumen of the large 
intestine.  
1.4.2.2 Cancer of the Colon 
Colon cancer is one of the top five most common cancers in both men and women, resulting in 
655,000 deaths per year worldwide (WHO, 2006). Colon cancer is defined by epithelial cells 
proliferating in an uncontrolled manner and invading the muscularis mucosa (Morson and Sobin, 
1976). This form of cancer may develop sporadically, influenced by diet and lifestyle choices, or it 
may result from one of two inherited conditions; familial adenomatous polyposis or hereditary non-
polyposis colorectal cancer. The colon will first demonstrate epithelial cell changes by the appearance 
of preneoplastic lesion, known as aberrant crypt foci, first discovered by Bird in 1987 (Bird, 1987).    
 
In the occurrence of colon cancer, the appearance of aberrant crypt foci will be followed by the 
development of adenomatous polyps, before invading the mucosa as a carcinoma (Janne and Mayer, 
2000). A series of molecular and histological changes are responsible for the progression of normal 
epithelial cells into colon carcinoma, including mutations to proto-oncogenes and tumor suppressor 
genes. A detailed progression of these events can be found in the Vogelstein model of colon 
carcinogenesis (Vogelstein et al., 1998). It is important to note that healthy epithelium in colonic 
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crypts is maintained by the balance between cell growth and cell death signals, and subtle changes to 
this balance occur prior to any neoplastic transformations (Shanmugathasin et al., 2000). 
 
1.4.2.3 Obesity and Colon Cancer 
 It is well established in epidemiological data that obesity is related to an increased risk for colon 
cancer (reviewed by Gunter and Leitzmann, 2006). Current reasoning for this relationship lies in the 
fact that an obese state of chronic inflammation is linked to insulin resistance, hyperglycemia, 
oxidative stress and excess lipid storage. The increased concentrations of insulin may induce a 
mitogenic effect within colon cells, while exposure to excess glucose and fatty acids may induce 
alterations in cell signaling (Gunter and Leitzmann, 2006). As oxidative stress and inflammatory 
markers are inducers of the sphingolipid pathway, which is pivotal in determining cell fate, it also 
becomes an important area to consider in the relationship between obesity and colon cancer risk.   
 
1.4.2.4 Sphingolipid Signaling and Colon Cancer 
While links between obesity and sphingolipid signaling remain unclear, a particular link between 
colon cancer and sphingolipid metabolism has been identified.  Changes in sphingomyelin 
metabolism are found to be associated with the development of tumors. Numerous studies have also 
looked at SK1 in the pathogenesis of colon cancer. It has been found that this enzyme is upregulated 
in colon tumor tissue and is necessary for promoting survival and proliferation of tumor cells 
(Kawamori et al., 2006; Kohno et al., 2006). Human colon cancers showed a greater than 50% 
decrease in ceramide levels compared to normal mucosa (Selzner et al., 2001). Furthermore, 
sphingosine-1 phosphate lyase, the enzyme which irreversibly degrades S1P, is downregulated in 
human colon cancer tissues compared to surrounding normal tissues, preventing degradation of the 
proliferative messenger (Oskouian et al., 2006). It appears that altering the sphingolipid pathway has 
important therapeutic potential, as increasing the ceramide levels in HT-29 colon cancer cells has 
been found to induce cell death, and adenoma size was decreased in rats that could not produce SK1 
(De Stefanis et al., 2002; Kohno et al., 2006). As evidence linking sphingolipid signaling in colon 
cancer builds, it becomes valuable to assess what role obesity plays in this signaling pathway. If the 
sphingolipid pathway is altered by obesity in colon tissue, this may change the colonic environment 
in which tumors can develop. 
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1.4.3 Zucker Obese Animal Models 
 
Zucker obese rats are commonly used as animal models for the study of obesity (see Fig. 4). They 
exhibit many of the characteristics common with human obesity, including hyperphagia, 
hyperglycemia and hyperinsulinemia. The Zucker obese rats (fa/fa) inherit their obesity as an 
autosomal recessive trait, as they are homozygous for nonfunctional leptin receptors compared to 
their lean counterparts (Zucker lean Fa/Fa or Fa/fa) (Zucker and Zucker 1961). Leptin is a hormone 
produced in adipose tissue that is responsible for regulating body weight and fat metabolism by 
signaling the hypothalamus to suppress appetite (Guyton et al., 2000). Nonfunctional leptin receptors 
result in the Zucker-obese rats overeating and becoming morbidly obese.  
 
The obese Zucker rats are therefore an excellent model to use in this study as the tissues of this 
obese model can be compared to the lean tissues of an animal model within the same strain (Zucker 
lean).  
 




Materials and Methods 
2.1 Materials 
Unless otherwise stated, all chemicals and reagents were purchased from Sigma Chemical Co., St. 
Louis, MO, USA. 
 
2.2 Animals 
Five-week-old female Ob (fa/fa) rats (n=14) and their lean (Fa/Fa) counterparts (n=12) were obtained 
from Charles River Laboratories (Wilmington, MA, USA). They were housed in suspended wire 
cages approximately 10 cm above sawdust bedding trays with a 12-h light/12-h dark cycle in the 
animal housing facility. Temperature and relative humidity were controlled at 22°C and 55%, 
respectively. All animals were acclimatized to these conditions for one week with free access to 
standard laboratory rodent chow and ad libitum drinking water until initiation of the experiment. All 
animals were cared for according to the guidelines of the Canadian Council on Animal Care and the 
protocol was approved by the University of Waterloo Animal Care committee.  
  
2.3 Diet, Body Weights, Termination 
The rats were fed synthetic diet AIN93. The rats remained on respective diets for nine weeks, after 
which, they were weighed, and terminated by CO2 asphyxiation.  Following termination, gross 
anatomy was observed and any pathologic abnormalities were recorded. Weights of liver, kidney, 




2.4 Sphingomyelinase Assay 
The activity of neutral and acidic sphingomyelinases in liver and colon were measured using the 
Amplex Red Sphingomyelinase Assay Kit (Molecular Probes, Eugene, OR). Amplex Red reagent 
(10-acetyl-3, 7 dihydroxyphenoxazine) measures sphingomyelinase activity indirectly, as it is a 
sensitive fluorogenic probe for H2O2. First sphingomyelinase hydrolyses sphingomyelin to yield 
ceramide and phosphorylcholine. Then the added alkaline phosphatase hydrolyses phosphorylcholine 
to choline, which can then be oxidized by choline oxidase to yield butane and H2O2. Finally, H2O2, in 
the presence of horseradish peroxidase, reacts with Amplex Red reagent in a 1:1 stoichiometry to 
generate highly fluorescent resorufin. 
The activity of neutral sphingomyelinase was analyzed using 250 μg of protein from each liver and 
colon sample diluted in 1x reaction buffer to make volume to 100 μL. The method was followed 
directly from the manufacturer’s instructions. 100 μL of each sphingomyelinase diluted samples was 
added to a 96 well plate. To each well, 100 μL assay solution was added containing 100 μM Amplex 
Red, 2 U/ml HRP, 0.2 U/mL cholesterol oxidase, 8 U/mL alkaline phosphatase, 0.5 mM 
sphingomyelin (made in 2% Triton X-100) with 0.1 M Tris-HCl and 10 mM MgCl2, pH 7.4. After 30 
min incubation at 37° C, the fluorescence was measured using excitation at 545±10 nm and emission 
detection at 590±10 nm.  
The activity of acidic sphingomyelinase was analyzed in a two-step reaction procedure. The 
sphingomyelinase containing samples were prepared using 250ug of protein from each sample diluted 
in a sodium acetate buffer (pH 5). 100 μL of each sample was added to the 96 well plate, and to each 
well was added 10μL of 5mM sphingomyelin solution. The plate was incubated for 1 h at 37 °C. The 
reaction was then placed on ice as the reaction mixture containing 100 μM Amplex Red, 2 U/ml HRP, 
0.2 U/mL cholesterol oxidase, 8 U/mL alkaline phosphatase, with 100 mM Tris-HCl, pH 8 was added 
and further incubated at 37° C for 30 min. The fluorescence intensities were measured with a filter set 
for excitation and emission detection at 545±10 and 590±10 nm, respectively. 
2.5 Tissue Lysate 
Tissues were stored at -80°C. 0.25 g of liver (from left lobe) and colon tissue (scraped mucosa) were 





Tris-HCl, 1% NP-40, 0.25% Sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM NaF) with 
freshly added protease inhibitors (1 μg/mL of Aprotinin, Leupeptin, Trypsin Inhibitor, Sodium 
Orthovandate) and then homogenized on ice using PT2100 Polytron homogenizer. The mixture was 
transferred into the microcentrifuge tubes, and lipids and cell debris were removed by centrifugation 
at 13,000 rpm for 20 min at 0°C. The supernatant (lysate) was then collected from below the top lipid 
layer and aliquoted in small amounts in pre-chilled eppendorf tubes and stored in -20°C for further 
analysis. 
 
2.6 Western Blot 
Antibody acquisitions were as follows: 
1. Rabbit polyclonal to SK1 in rat, human and mouse (Abgent Inc., San Diego, CA, USA; 
catalogue # AP7237c).  
2. Goat polyclonal to ceramidase in rat, human and mouse (Santa Cruz Biotechnologies, Santa 
Cruz, CA, USA; catalogue # sc-28486).  
3. Rabbit polyclonal to Bax and Bcl-2 in rat, human and mouse (Abcam Inc., Cambridge, MA, 
USA; catalogue #s  ab7977 and ab7973, respectively).  
4. Bovine Anti-goat IgG-HRP (Santa Cruz Biotechnologies, Santa Cruz, CA, USA; catalogue # 
sc-23500).  
5. Goat Anti-rabbit IgG-HRP (Cell Signaling Technology Inc.,  Boston, MA, USA; catalogue # 
7074). 
 
 Protein Assay 
The Bio-Rad colorimetric protein assay, based on Bradford method, was used to determine the total 
protein content using bovine serum albumin as a standard. Protein solution was assayed in duplicates 
in 96 well plates and the absorbance was measured using Bio-Rad 3550-UV Microplate Reader at 595 
nm. 
 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The protein samples were subjected to 10 % SDS-PAGE using the Mini-Protean-BioRad II apparatus 




(using samples containing 10, 25, 50, 75, 100, 150, 200 ug of protein) to determine the optimal 
amount of protein to load for each antibody. 50 μg of protein was added to each sample for all 
antibodies with the exception of sphingosine kinase, which required 100 μg of protein for each liver 
sample and 150 μg of protein for each colon sample for optimal detection. Liver samples were mixed 
with equal volume of 2x SDS Laemmli buffer (Sigma Chemical).  Colon samples were mixed with 
0.25 homogenate volume of 5x Laemmli buffer to decrease total sample size. All samples were boiled 
for 5 min at 90°C. Then the equal protein samples were loaded in 15-well gels and the proteins 
separated in SDS-PAGE at 120V for 90 min. As the colon samples for SK1 were too large, the lean 
samples and obese samples were run separately in 10-well gels. A positive control (liver) was 
included in these gels to minimize background and account for gel-to-gel variability.  
 Western Blot 
Proteins were transferred from gels onto methanol soaked 0.45 μm PVDF membranes (Pall Corp. FL, 
USA.) The Trans-Blot Semi-Dry transfer cell system (Bio-Rad Laboratories Ltd, Carlsbad, CA, USA) 
at 20V for 30 min was used for SK1 immunoblots. For all other blots, transfer was completed using 
the Mini-Trans-Blot Electrophoretic Transfer Cell (Bio-Rad Laboratories Ltd, Canada) at 100V for 60 
min. The gels were stained with Coomassie Brilliant Blue to confirm proper transfer. SK1 blots were 
washed briefly in 10% TBS-T solution and were incubated in TBS-T containing bovine serum 
albumin (5%) blocking buffer for 1 h at room temperature to block non-specific binding, then probed 
with SK1 primary antibodies for 1 h at room temperature, followed by overnight incubation at 4°C.   
 
Blots for ceramidase, Bax, and Bcl-2 also followed the above protocol except the blocking was 
carried out in TBS-T containing 5% skim milk for 1 h at room temperature and overnight at 4°C. 
Blots were then incubated in their respective primary antibodies for 2.5 h at room temperature. After 
incubation in primary antibody, all immunoblots were washed three times with TBS-T and then 
incubated with peroxidase conjugated secondary antibodies in a 1% blocking solution for 1.5 h. After 
washing three times in TBS-T, the blots were incubated for five minutes with ECL plus (Amersham 
Biosciences Canada, GE Healthcare Bio-Sciences Inc.,Quebec, Canada) and developed using X-ray 
film (Fisher Scientific Company, Ottawa, ON, Canada). Finally, densitometric analysis was 
conducted using AlphaEaseFC software. The membranes were stained with Ponceau-S to confirm 
equal loading and were used to normalize the integrated density values for quantification. 
Densitometry analysis was performed using a Visible Imaging System equipped with AlphaEaseFC 
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software (Alpha Innotech, San Leandro, CA). The blots for liver samples were washed in TBS-T and 
reprobed with beta-actin as a secondary control for equal loading. For colon membranes, ponceau 
staining alone was used as control as beta-actin does not show up consistently in colon samples.  
 
 
2.7 Sphingolipid Quantitative Analysis 
Sphingomyelin, ceramide, ceramide-1 phosphate, sphingosine and sphingosine-1-phosphate were 
analyzed by high-performance liquid chromatography (HPLC) -tandem mass spectroscopy (MS) by 
the lab of Dr. J Beilawski (Lipidomic Core, Medical University of South Carolina, Charleston, SC). A 
detailed description of the method can be found in the journal of Methods (Beilawski et al., 2006). 
Briefly, 0.5 grams of each liver and colon sample were homogenized in tissue buffer and fortified 
with internal standards, 17-sphingosine, 17-S1P, 18C17-SM and 17C16-ceramide.  Protein 
concentration was determined in each sample (Bio-Rad Protein Assay) and then sphingolipids were 
extracted using a solution of iso-propanol: water: ethyl acetate (30:10:60). Samples were centrifuged 
for 10 min at 4000 rpm and supernatants collected. Organic extracts were evaporated under N2 gas 
and were reconstituted in methanol containing 0.2% formic acid. Samples were then analyzed using 
TSQ 7000 LC/MS system. Quantitative analysis is based on calibration curves generated by spiking 
bovine serum albumin with known amounts of target synthetic standards and an equal amount of 
internal standard. The calibration curves are generated by plotting the peak area ratios of sphingolipid 
to the respective internal standards against concentration using a linear regression model.  
 
2.8 Statistical Analysis 
Statistical analysis of the data was performed using SPSS statistical software (SPSS Inc., Chicago, IL, 
USA). A comparison between lean and obese groups was performed and differences were determined 
using independent samples t-test, at a significance level of P <0 .05. Statistical analysis between 




Chapter 3                                                                        
Results 
3.1 Animal weights  
Body mass of obese rats were significantly higher than their lean counterparts (Table 1). 
 













a means± s.e.m. at time of termination (9 weeks); * significantly different from the lean control group ( P<0.05; 







3.2 Lean and Obese Liver Tissue Results 
  Liver observations 
Obese Zucker livers were significantly larger than the lean livers. Furthermore, obese Zucker liver 
tissue appeared pale and creamy colored compared to the darker red of the lean livers. Shown below 
is previous liver histology from Zucker obese and lean control rats (Fig.5). Obese Zucker liver shows 
lipid accumulation within the hepatocytes demonstrating hepatic steatosis, while the lean liver shows 














Figure 5: Haematoxylin and eosin stained liver histology of:  (a) Zucker obese rat liver tissue; (b) Zucker 
lean rat liver tissue. 
After termination, a segment of liver was fixed in a buffered formalin solution. Transverse sections (4µm) were 
stained with haematoxylin (staining the nuclei black) and eosin (staining the cytoplasm pink). Obese liver (a) 
shows lipid accumulation in hepatocytes, and lean liver (b) shows normal liver histology.   





   
  Sphingomyelinase Activity in Liver  
There were no significant differences in acidic and neutral sphingomyelinase levels in lean and obese 
liver tissue (Figs. 6 and 7). 
 

































Figure 6: Acidic sphingomyelinase in lean and obese liver tissue. 
Mean sphingomyelinase levels (N=6 per group) are expressed in relative fluorescence units per µg protein ± 








































Figure 7: Neutral sphingomyelinase in lean and obese liver tissue.  
Mean sphingomyelinase levels (N=6 per group) are expressed in relative fluorescence units per µg protein ± 




3.2.3 Ceramidase Expression in Liver  
Ceramidase bands were observed at a band size of 55kDa for both lean and obese liver tissue. This 
band size is consistent with the ceramidase 55kDa precursor protein. Ceramidase protein expression 








     
 



























     
Figure 8: Western blot for ceramidase in lean and obese liver and ponceau stain. 
3 representative bands from each group (A) are shown with beta-actin control bands (B). Samples containing 50 
µg of protein were separated by 10% SDS-PAGE and transferred onto PVDF membranes.  Following 
incubation with primary anti-ceramidase at a1:200 dilution and secondary HRP-conjugated anti-goat at a 1:10 
000 dilution, the blots were developed on X-ray film using ECL-Plus substrate. Membranes were then stained 
with Ponceau-S for equal loading control (C). Bar graphs (D) represent mean levels of ceramidase in lean and 
obese liver. All ceramidase bands were normalized to their respective ponceau bands; *significantly different 






 Sphingosine Kinase Expression in Liver  
Sphingosine kinase bands were observed at the predicted band size of 43 kDa for both lean and obese 
liver tissue. A second band appeared just below the 43 kDa mark in obese liver tissue that was not 
observed in lean tissue. SK1 protein expression is significantly higher in lean liver tissue compared to 


























Figure 9: Western blot for SK1 in lean and obese liver.  
3 representative bands from each group (A) are shown with representative bands from their respective ponceau 
stains (B). A second band is observed in obese liver, while only a single band appears for lean liver. Samples 
containing 100 µg of protein were separated by 10% SDS-PAGE gel and transferred onto PVDF membranes.  
Following incubation with primary anti-SK1 at a1:500 dilution and secondary HRP-conjugated anti-rabbit at a 
1:3000 dilution, the blots were developed on X-ray film using ECL-Plus substrate. Membranes were then 
stained with Ponceau-S for equal loading control. Bar graphs (C) represent expression levels of SK1 in lean and 
obese liver, expressed as percentage lean liver. For obese liver, only the upper band that appeared at the 
expected 43 kDa mark was quantified. All SK1 expression bands were normalized to ponceau bands; 




3.2.5 Bcl-2 Expression in Liver  
Bcl-2 bands were observed at the predicted band size of 30 kDa for both lean and obese liver tissue. 
Lean liver tissue shows greater Bcl-2 levels than the obese liver. Bcl-2 protein expression is 
significantly higher in lean liver tissue compared to obese (Fig. 10).  
 
 





















Figure 10: Western blot for Bcl-2 in lean and obese liver. 
3 representative bands from each group (A) are shown with representative bands from their respective ponceau 
stains (B). Samples containing 50 µg of protein were separated by 10% SDS-PAGE gel and transferred onto 
PVDF membranes.  Following incubation with primary anti-Bcl-2 at a1:500 dilution and secondary HRP-
conjugated anti-rabbit at a 1:3000 dilution, the blots were developed on X-ray film using ECL-Plus substrate. 
Membranes were then stained with Ponceau-S for equal loading control. All Bcl-2 expression bands were 
normalized to ponceau bands. Bar graphs (C) represent expression levels of Bcl-2 in lean and obese liver, 





 Bax Expression in Liver  
Bax bands were observed at the predicted band size of 21 kDa for both lean and obese liver tissue. 
Faint bands also appeared at the 42kDa mark, as predicted by antibody specifications, as Bax 
regularly forms homodimers.  Bax protein expression is significantly higher in obese liver tissue 

























Figure 11: Western blot for Bax in lean and obese liver. 
3 representative bands from each group (A) are shown with representative bands from their respective ponceau 
stains (B). Samples containing 50 µg of protein were separated by 10% SDS-PAGE gel and transferred onto 
PVDF membranes.  Following incubation with primary anti-Bax at a1:500 dilution and secondary HRP-
conjugated anti-rabbit at a 1:3000 dilution, the blots were developed on X-ray film using ECL-Plus substrate. 
Membranes were then stained with Ponceau-S for equal loading control. All Bax expression bands were 
normalized to ponceau bands. Bar graphs (C) represent expression levels of Bax in lean and obese liver, 






3.2.7 Sphingomyelin Content in Liver  
LC-MS (liquid chromatography-mass spectroscopy) analysis results show that various species of SM 
are altered in obese liver tissue compared to lean. SM species differ in the number of carbons and 
number of double bonds in their fatty acid chain. C16-SM is significantly higher in obese liver while 
C22- and C24-SM levels are significantly lower in obese liver (Fig. 12). C22:1-, C26- and C26:1- SM 
are also significantly lower in obese liver tissue compared to lean (Fig. 13). 
 
 

























Figure 12: C16, C22 and C24 sphingomyelin levels in lean and obese liver tissue  
SM levels are shown in pmole/mg protein ± s.e.m.; *significantly different from lean group (P<0.05; N=5). 
SMs were quantified by HPLC-MS. 18C17-SM was used as an internal standard. After sphingolipid extraction, 




























Figure 13: C22:1, C26, C26:1 sphingomyelin levels in lean and obese liver tissue 
SM levels are shown in pmole/mg protein ± s.e.m.; *significantly different from lean group (P<0.05; N=5). 
SMs were quantified by HPLC-MS. 18C17-SM was used as an internal standard. After sphingolipid extraction, 
samples containing 1mg of protein were analyzed using TSQ 7000 LC/MS system.  
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Other SM species, C14-, C18-, C18:1-, C20-, C20:1- and C24:1- SM, did not differ significantly 
between the two groups. Calculation of total SM shows lower SM content in obese liver tissue 























Figure 14: Total sphingomyelin content in lean and obese liver tissue 
SM levels are shown in pmole/mg protein ± s.e.m. N=5 per group. SMs were quantified by HPLC-MS. 18C17-
SM was used as an internal standard.  After sphingolipid extraction, samples containing 1mg of protein were 
















The relative differences in SM species compositions between the lean and obese livers are depicted in 
the following stacked graph (Fig. 15). 
 





































Figure 15: Sphingomyelin species composition in lean versus obese liver tissue 
SM species levels are shown as a percentage of total SM content in this stacked graph; *significantly different 
from lean group (P<0.05; N=5). Significant differences can be observed for C16-, C22-, C22:1-, C24-, and C26-
SM.  Note that significant differences were also observed for C26:1-SM, but the levels of this species were too 
low to be visible in this figure.  
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3.2.8 Ceramide Content in Liver  
LC-MS analysis shows that various ceramide species are significantly altered in obese liver tissue 
compared to lean. Ceramide species differ in the number of carbons and number of double bonds in 
their fatty acid chain. C16-ceramide is significantly lower in obese tissue, while C22-, C24:1-
ceramides are higher in obese tissue (Fig. 16). C18-, C20- and C24:0- ceramide levels are also 
significantly higher in an obese state (Fig. 17).  
 























Figure 16: C16, C22 and C24:1 ceramide levels in liver tissue 
Ceramide levels are shown in pmole/mg protein ± s.e.m.; *significantly different from lean group (P<0.05; 
N=5).  Ceramides were quantified by HPLC-MS. 17C16-ceramide was used as an internal standard. After 





























Figure 17: C18, C20 and C20:4 ceramide levels in lean and obese liver tissue 
Ceramide levels are shown in pmole/mg protein ± s.e.m.; *significantly different from lean group (P<0.05; 
N=5).. Ceramides were quantified by HPLC-MS. Internal standard 17C16-ceramide was used.  After 




Levels of C18:1, C14, C20:1, C22:1, C24, C26, and C26:1 ceramide did not differ significantly 
between lean and obese groups. Total ceramide content was found to be higher in obese liver 


























Figure 18: Total ceramide content in lean and obese liver tissue 
Ceramide levels are shown in pmole/mg protein ± s.e.m. N=5 per group. Ceramides were quantified by HPLC-
MS. 17C16-ceramide was used as an internal standard.  After sphingolipid extraction, samples containing 1mg 
















The relative differences in ceramide species compositions between the lean and obese livers are 
depicted in the following stacked graph (Fig. 19). 
 










































Figure 19: Ceramide species composition in lean versus obese liver tissue 
Ceramide species levels are shown as a percentage of total ceramide content in this stacked graph; 
*significantly different from lean group (P<0.05; N=5). Significant differences can be observed for C16-, C18-, 
C20-, C22-, C24-, and C24:1-ceramide.   
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3.2.9 Ceramide-1-Phosphate Content Liver  
LC-MS analysis shows that two C1P species are significantly altered in obese liver tissue compared 
to lean. C18- and C18:1- C1P levels are both significantly lower in an obese state (Figs.20 and 21). 
C16-C1P is lower in obese tissue, although not significantly. All other C1P species are below 
























Figure 20: C18- ceramide-1-phosphate in lean and obese liver tissue 
Ceramide levels are shown in pmole/mg protein ± s.e.m.; *significantly different from lean group (P<0.05; 
N=5).   C1P is quantified by HPLC-MS.  After sphingolipid extraction, samples containing 1mg of protein were 

























Figure 21: C18:1- ceramide-1-phosphate in lean and obese liver tissue 
Ceramide levels are shown in pmole/mg protein ± s.e.m.; *significantly different from lean group (P<0.05; 
N=5).C1P is quantified by HPLC-MS.  After sphingolipid extraction, samples containing 1mg of protein were 
analyzed using TSQ 7000 LC/MS system.  
 






















Figure 22: Total ceramide-1-phosphate content in lean and obese liver tissue 
Ceramide levels are shown in pmole/mg protein ± s.e.m.; *significantly different from lean group (P<0.05; 
N=5). C1P is quantified by HPLC-MS.  After sphingolipid extraction, samples containing 1mg of protein were 









 Sphingosine Content in Liver  
LC-MS analysis shows that sphingosine is higher in obese liver compared to lean though the two 
groups do not differ significantly for N=5 per group. (Fig. B1 in appendix). 
 
 Sphingosine-1-Phosphate Content in Liver  
S1P levels were below detection level in LC-MS analysis in liver. 17C-S1P was used as an internal 
standard. Samples containing 1mg of protein were analyzed using TSQ 7000 LC/MS system. S1P is 
the only sphingolipid undetectable in the 1mg samples used; therefore S1P must exist at much lower 
levels compared to other sphingolipids. Only 1-2 samples per group had detectable levels of S1P so 
statistical analysis could not be completed. It is inconclusive whether S1P levels differ significantly 




3.3 Lean and Obese Colon Tissue Results 
 Sphingomyelinase Activity in Colon 
Sphingomyelinase levels did not differ significantly between groups (Figs. 24 and 25). 
 

































Figure 23: Acidic sphingomyelinase in lean and obese colon tissue 
Mean sphingomyelinase levels (N=6 per group) are expressed in relative fluorescence units per µg protein ± 
s.e.m. See materials and methods for details. 
 































Figure 24: Neutral sphingomyelinase in lean and obese colon tissue 
Mean sphingomyelinase levels (N=6 per group) are expressed in relative fluorescence units per µg protein ± 






 Ceramidase Expression in Colon 
Ceramidase bands were observed at a band size of 40kDa for both lean and obese liver tissue. This 
band size demonstrates that the ceramidase in colon is present as the mature 40kDa subunit 
ceramidase protein. Ceramidase protein expression is significantly higher in obese colon tissue 
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Figure 25: Western blot for ceramidase in lean and obese colon. 
3 representative bands from each group (A) are shown with representative bands from their respective ponceau 
stains (B). Samples containing 50 µg of protein were separated by 10% SDS-PAGE gel and transferred onto 
PVDF membranes.  Following incubation with primary anti-ceramidase at a1:200 dilution and secondary HRP-
conjugated anti-goat at a 1:10,000 dilution, the blots were developed on X-ray film using ECL-Plus substrate. 
Membranes were then stained with Ponceau-S for equal loading control. Bar graphs (C) represent mean levels 
of ceramidase in lean and obese colon. All ceramidase bands were normalized to their respective ponceau 








 Sphingosine Kinase Expression in Colon 
Sphingosine kinase bands were observed at the predicted band size of 43 kDa for both lean and obese 
liver tissue. A wider band or possible doublet band is observed for both groups. However, altering the 
running time or gel concentration during electrophoresis did not help achieve band separation so the 





























Figure 26: Western blot for SK1 in lean and obese colon.  
3 representative bands from each group (A) are shown with representative bands from their respective ponceau 
stains (B). Samples containing 150 µg of protein were separated by 10% SDS-PAGE gel and transferred onto 
PVDF membranes.  Following incubation with primary anti-SK1 at a1:500 dilution and secondary HRP-
conjugated anti-rabbit at a 1:3000 dilution, the blots were developed on X-ray film using ECL-Plus substrate. 
Membranes were then stained with Ponceau-S for equal loading control. All SK1 expression bands were 
normalized to ponceau bands. Bar graphs (C) represent expression levels of SK1 in lean and obese colon, 






 Bcl-2 Expression in Colon Tissue  
Bcl-2 bands were observed at the twice the predicted band size of 30 kDa for both lean and obese 
colon tissue, appearing at the 60kDa mark. As this band size is unpredicted by antibody 
specifications, it may not represent Bcl-2 and may be demonstrating cross reactivity of the antibody. 

























Figure 27: Western blot for Putative Bcl-2 in lean and obese colon. 
3 representative bands from each group (A) are shown with representative bands from their respective ponceau 
stains (B). Samples containing 50 µg of protein were separated by 10% SDS-PAGE gel and transferred onto 
PVDF membranes.  Following incubation with primary anti-Bcl-2 at a1:500 dilution and secondary HRP-
conjugated anti-rabbit at a 1:3000 dilution, the blots were developed on X-ray film using ECL-Plus substrate. 
Membranes were then stained with Ponceau-S for equal loading control. All Bcl-2 expression bands were 
normalized to ponceau bands. Bar graphs (C) represent expression levels of putative Bcl-2 in lean and obese 





3.3.5 Bax Expression in Lean versus Obese Colon Tissue  
Bax bands were observed at an expected band size of 42 kDa for both lean and obese liver tissue, 
demonstrating that Bax proteins are present as homodimers in colon tissue. Bax protein expression is 
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Figure 28: Western blot for Bax in lean and obese colon. 
3 representative bands from each group (A) are shown with representative bands from their respective ponceau 
stains (B).  Samples containing 50 µg of protein were separated by 10% SDS-PAGE gel and transferred onto 
PVDF membranes.  Following incubation with primary anti-Bax at a1:500 dilution and secondary HRP-
conjugated anti-rabbit at a 1:3000 dilution, the blots were developed on X-ray film using ECL-Plus substrate. 
Membranes were then stained with Ponceau-S for equal loading control. All Bax expression bands were 
normalized to ponceau bands. Bar graphs (C) represent expression levels of Bax in lean and obese colon, 






 Sphingomyelin Content in Colon 
No significant differences in sphingomyelin species are observed between lean and obese colon 
tissue. (Fig. B2 in appendix).  
 
Unlike liver tissue, no differences are observed in SM species composition between lean and obese 
colon (Fig. 29). 



























Figure 29: Sphingomyelin species composition in lean versus obese colon tissue 
SM species levels are shown as a percentage of total SM content in this stacked graph. No significant 





 Ceramide Content in Colon  
C24:1 ceramide is significantly higher in obese colon tissue compared to lean (Fig. 30). No 
significant differences were observed for any other ceramide species in colon tissue. Total ceramide 
levels were higher in obese tissue, though not significantly (Fig. B3 in appendix). 
 

























Figure 30: C24:1 ceramide levels in lean and obese colon 
Ceramide levels are shown in pmole/mg protein ± s.e.m; *significantly different from lean group (P<0.05; 
N=5).Ceramides were quantified by HPLC-MS. Internal standard 17C16-ceramide was used.  After 













The relative differences in ceramide species compositions between the lean and obese colons are 
depicted in the following stacked graph (Fig. 31). 
 





































Figure 31: Ceramide species composition in lean versus obese colon tissue 
Ceramide species levels are shown as a percentage of total ceramide content in this stacked graph:*significantly 





 Ceramide-1-Phosphate Content in Colon  
LC-MS analysis shows that only two C1P species are detectable in colon, C18- and C16-C1P. C18-
C1P levels are significantly lower in an obese state (Fig.32). C16-C1P is lower in obese tissue, 
although not significantly. All other C1P species are below detection level. Total C1P levels show 

























Figure 32: C18- ceramide-1-phosphate in lean and obese colon tissue 
Ceramide-1-phosphate levels are shown in pmole/mg protein ± s.e.m.;*significantly different from lean group 
(P<0.05; N=5). C1P is quantified by HPLC-MS.  After sphingolipid extraction, samples containing 1mg of 
























Figure 33: Total ceramide-1-phosphate content in lean and obese colon tissue 
Ceramide-1-phosphate levels are shown in pmole/mg protein ± s.e.m.;*significantly different from lean group 
(P<0.05; N=5). C1P is quantified by HPLC-MS.  After sphingolipid extraction, samples containing 1mg of 








 Sphingosine Content in Colon 
LC-MS analysis shows that sphingosine is higher in obese colon tissue compared to lean though the 
two groups do not differ significantly for N=5 per group (Fig. B4 in appendix).  
 
 Sphingosine-1-Phosphate in Colon 
S1P levels were below detection level in LC-MS analysis in colon. 17C-S1P was used as an internal 
standard. Samples containing 1mg of protein were analyzed using TSQ 7000 LC/MS system. S1P is 
the only sphingolipid undetectable in the 1mg samples used; therefore S1P must exist at much lower 
levels compared to other sphingolipids. Only 1-2 samples per group had detectable levels of S1P so 
statistical analysis could not be completed. It is inconclusive whether S1P levels differ significantly 
between lean and obese groups in colon.  
 
3.4 Tissue Specific Differences 
 Sphingomyelinase Activity in Liver versus Colon 
Comparisons between liver and colon tissue show that sphingomyelinase activity differs significantly 
between tissues. Sphingomyelinase activity is higher in lean colon tissue compared to liver tissue 
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Figure 34: Neutral and acidic sphingomyelinase activity in lean liver and colon 
Mean sphingomyelinase levels are expressed in relative fluorescence units per µg protein ± s.e.m.; values 
without a common letter (x,,z) differ significantly (P<0.05, N=6). See materials and methods for details. 
 
Neutral and Acidic Sphingomyelinase  in Obese 











































Figure 35: Neutral and acidic sphingomyelinase activity in obese liver and colon 
Mean sphingomyelinase levels are expressed in relative fluorescence units per µg protein ± s.e.m.; values 
without a common letter (x,,z) differ significantly (P<0.05, N=6). See materials and methods for details. 
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3.4.2 Sphingolipids in Liver versus Colon 
LC-MS results showed that there are tissue specific differences between sphingolipids. A paired-
samples t-test was run for each sphingolipid, comparing liver and colon tissue from the same rat.  
3.4.2.1 Sphingomyelin Content in Liver versus Colon 
Total sphingomyelin levels are significantly higher in colon tissue compared to liver tissue (Figs.36 
and 37). 
 






















Figure 36: Total sphingomyelin content in lean liver and colon tissue 
SM levels are shown in pmole/mg protein ± s.e.m.;*significantly different from lean group (P<0.05; N=5). SMs 
were quantified by HPLC-MS. 18C17-SM was used as an internal standard.  After sphingolipid extraction, 



























Figure 37: Total sphingomyelin content in obese liver and colon 
SM levels are shown in pmole/mg protein ± s.e.m.;*significantly different from lean group (P<0.05; N=5). SMs 
were quantified by HPLC-MS. 18C17-SM was used as an internal standard.  After sphingolipid extraction, 
samples containing 1mg of protein were analyzed using TSQ 7000 LC/MS system.  
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A shift in SM species composition can be observed between liver and colon tissue as illustrated in the 
stacked graph below (Fig. 38).  






























Figure 38: Sphingomyelin species composition in liver and colon tissue 
This graph provides a qualitative visualization of differences in SM species between tissue types. SM species 
levels are shown as a percentage of total SM content in this stacked graph. 
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3.4.2.2 Ceramide Content in Liver versus Colon 
Comparison of ceramide content in liver and colon finds that total ceramide is significantly higher in 
colon tissue (Figs. 39 and 40). 



















Figure 39: Total ceramide content in lean liver and colon 
Ceramide levels are shown in pmole/mg protein ± s.e.m.;*significantly different from lean group (P<0.05; 
N=5). Ceramides were quantified by HPLC-MS. 17C16-ceramide was used as an internal standard. After 
























Figure 40: Total ceramide content in obese liver and colon 
Ceramide levels are shown in pmole/mg protein ± s.e.m.;*significantly different from lean group (P<0.05; 
N=5). Ceramides were quantified by HPLC-MS. 17C16-ceramide was used as an internal standard. After 




A shift in SM species composition can be observed between liver and colon tissue as illustrated in 
the stacked graph below (Fig.41). 









































Figure 41: Ceramide species composition in liver and colon tissue 
This graph provides a qualitative visualization of differences in ceramide species between tissue types. 





3.4.2.3 Sphingosine Content in Liver versus Colon 
Sphingosine levels do not differ significantly in comparing liver and colon tissue (Figs. B5 and B6 in 
appendix). 
 
3.4.2.4 Ceramide-1-Phosphate in Liver versus Colon 
C1P levels are significantly lower in colon compared to liver (Figs.42 and 43). 






















Figure 42: Total ceramide-1-phosphate content in lean liver and colon 
Ceramide-1-phosphate levels are shown in pmole/mg protein ± s.e.m.;*significantly different from lean group 
(P<0.05; N=5). C1P is quantified by HPLC-MS.  After sphingolipid extraction, samples containing 1mg of 



























Figure 43: Total ceramide-1-phosphate content in obese liver and colon 
Ceramide-1-phosphate levels are shown in pmole/mg protein ± s.e.m. .;*significantly different from lean group 
(P<0.05; N=5). C1P is quantified by HPLC-MS.  After sphingolipid extraction, samples containing 1mg of 





Chapter 4                                                                         
Discussion 
 
In this study, an obese genotype impacted the sphingolipid signaling pathway in both liver and colon. 
To our knowledge, this is the first study comparing sphingolipid signaling in obese versus lean liver 
and colon tissue. The results show a clear tissue-specific alteration in sphingolipid signaling leading 
to the proposal that this pathway may be involved in the pathogenesis related to obesity.   
4.1 Liver tissue 
 Sphingolipid Signaling Pathway in Liver Tissue 
This study was undertaken to determine if the sphingolipid pathway is altered in a state of obesity in 
hepatic steatotic liver. It was hypothesized that the pro-inflammatory environment of the diseased 
fatty liver would result in an upregulation of the sphingolipid signaling pathway. Quantifying 
sphingolipids as well as the key sphingolipid enzymes did show notable differences in the 
sphingolipid pathway between obese and lean liver.    
The liver is a complex and multi-functional organ and liver disease is a serious occurrence 
commonly linked to obesity. Zucker obese rats exhibit hepatic steatosis demonstrated by an 
accumulation of lipids in their hepatocytes (Figure 5). This may be attributed to insulin resistance and 
increased release of free fatty acids from adipose tissue (Angulo, 2002; Browning and Horton, 2002). 
In addition, hepatic steatosis is linked to oxidative stress and inflammation, and both reactive oxygen 
species and inflammatory molecules have been reported as being present in higher levels in a state of 
obesity (Bohlen, 2004; Chitturi et al., 2001). It is also well established that the sphingolipid signaling 
pathway is activated under conditions of cellular stress, including induction of SMase by TNF-α, IL-
1β, free fatty acids, and ROS (Woodock, 2006; Ogretmen, 2006; Kolesnick, 2002).  
When SMase activity was compared between obese and lean liver tissue, there was a trend toward 
a higher level of SMase in obese liver tissue. While both neutral and acidic SMase activity was found 
to be higher in obese tissue compared to lean in all repetitions of the assay, the differences were not 
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statistically significant. With the increased levels of inflammatory molecules and reactive oxygen 
species in obese tissue, it is interesting that there are not more significant differences in SMase 
activity between groups; however, many factors may contribute to the results obtained. Firstly, it 
should be noted that the animals in this study were not induced in any way to activate the pathway, 
and rather were in a steady state level of obesity. In studies looking at activation of SMase, inducers 
such as TNF-α or ROS are added in excess amounts. It cannot be expected that a steady state level of 
cellular stressors would affect the sphingolipid pathway to the same extent as shocking the cells with 
excess amounts of these molecules. Secondly, the enzyme assay is limited in that it only measures the 
level of available enzyme waiting to be stimulated. Thus enzyme that is already active or being used 
up is not being accounted for. Furthermore, it does not take into account turnover rate of the enzyme 
or the level of available substrate.  
LC-MS quantification of SM shows a trend toward lower SM levels in obese liver tissue compared 
to lean. There are many different biological species of SM, distinguished by the number of carbon 
atoms and number of double bonds in their fatty acid chain.  When individual SM species were 
compared between obese and lean liver, it was found that several species of SM are significantly 
lower in the obese tissue (Figs. 12 and 13). Specifically, long chain C22-, C22:1-, C24-, C26-, and 
C26:1- sphingomyelins were lower in obese liver tissue suggesting that either the longer chain SMs 
are being hydrolyzed to ceramide by activated SMase in obese tissue or that lean and obese rats 
simply differ in the composition of SMs present in their hepatocyte membranes. If the latter were 
true, it would be expected that with five species of SM lower in obese tissue, other species of SM 
must be present at higher levels, but in fact, only one SM species, C16-SM was found to be higher in 
obese liver tissue (Fig.12). While this does suggest a shift in SM species between lean and obese 
groups, it is possible that the longer chain SMs are being hydrolyzed by active SMase, thus 
explaining their lower levels in obese tissue.  
Though the level of total SM is not significantly lower in the obese group, a very small sample size 
was used (N=5) (Fig.14). A larger sample size would help clarify if there are significant differences 
between SM levels in lean and obese liver tissue. It must also be noted that the sphingolipid pathway 
is not a stagnant one. While SM hydrolysis may be occurring, SM synthesis can also be taking place 
within the cells, resulting in SM regeneration, and perhaps certain species of SM are generated more 
frequently.  The trend toward lower SM in obese liver coincides with a recent study that found SM to 
be downregulated in livers from obese mice compared to their lean counterparts (Yetukuri, 2007).  
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The hydrolysis of SM by SMase results in ceramide production. Examining ceramide content in 
lean and obese groups shows further sphingolipid differences. While there is a trend toward higher 
ceramide levels in obese liver tissue, total ceramide content is not significantly higher in obese tissue 
(Fig.18). Once again, a larger sample size would be more conclusive in deciding if total ceramide is 
significantly higher in obese liver, though the small sample size used here is still enough to see 
differences amongst ceramide species between groups. 
Like SM, ceramide can be divided into species depending on the number of carbon atoms and 
double bonds are present in the fatty acid chain. When the various species were compared between 
groups, it was found that C22-, C24:1-, C18-, C20-, and C24:0-ceramide were present at higher levels 
in obese tissue (Figs. 16 and 17). Interestingly, C16-ceramide is significantly lower in obese tissue 
(Fig.16). The upregulation of some species and downregulation of anther indicates a shift in ceramide 
species composition (Fig.19). This supports a recent finding showing higher ceramide concentration 
in livers of obese mouse compared to a lean mouse (Yetukuri et al, 2007). Specifically, the mouse 
study showed that C18- and C16-ceramide were the most abundant ceramide species and were 
upregulated in obese liver. These upregulated ceramide species correlated with same chain length 
triacylglyerol, suggesting that accumulation of reactive ceramide species increase in the liver of the 
obese mice proportionally to the accumulation of triacylglycerol, which is a characteristic of hepatic 
steatosis (Yetukuri et al., 2007). In our analysis, we found that C16, C24 and C24:1-ceramides were 
the most abundant in liver tissue, and perhaps this can be linked to the chain length of triacylglycerols 
present in rat tissue that differ from those found in the mouse model. It is interesting to note the shift 
in abundant ceramide species observed between the obese mouse model and the rat used in our study. 
While the upregulation of C18-ceramide in obese liver is similar between the two models, the C16-
ceramide concentration was downregulated in rat obese liver tissue unlike the mouse tissue (Yetukuri 
et a., 2007). However, this coincides with our finding that C16-SM is significantly higher in obese 
liver tissue suggesting that less C16-SM is being hydrolyzed by SMase to produce C16-ceramide.   
The production and accumulation of ceramide is important in generating an apoptotic signal within 
the cell. The trend toward higher ceramide levels and altered ceramide species in obese tissue may 
contribute to the pathogenesis of the steatotic liver. Of course, other sphingolipid signaling molecules 
in the pathway must be examined as well so as to determine the overall balance in signaling 
molecules. Ceramide, once generated, has many fates within a cell. It can be converted back to SM, 
deacetylated to sphingosine, or phosphorylated to C1P. Ceramide can be phosphorylated by CerK to 
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form C1P. Quantification of C1P shows that C18- and C18:1-C1P (figures) are significantly 
downregulated in obese liver, as well as total C1P levels (figure). All longer chain species of C1P 
were below detection level. This downregulation of C1P is important as C1P opposes apoptotic 
ceramide activity. An overall depression in C1P indicates that the obese liver cells are receiving less 
stimulation for survival and proliferation.  
Ceramide can also be prevented from accumulating in the cell via conversion to sphingosine. 
Ceramidase deacetylates ceramide, producing sphingosine. When this enzyme was analyzed by 
western blot, it was found that ceramidase expression was significantly higher in obese liver. In liver 
tissue, ceramidase bands were observed at a size of 55kDa, consistent with the expected size of 
ceramidase precursor protein. Ceramidase is synthesized as a 55kDa lysosomal protein. This protein 
can be cleaved into two subunits, alpha and beta, of 13kDa and 40 kDa respectively (Bernardo et al., 
1995). Little is known about inducers of ceramidase, however, it has been suggested that platelet 
derived growth factor (PDGF) and insulin-like growth factor (IGF) can activate ceramidase, leading 
to sphingosine production (Suzuki et al., 2004). Ceramidase overexpression in obese liver tissue may 
indicate the tissue trying to compensate for high ceramide levels in the active sphingolipid pathway. 
Ceramidase may play a protective role by converting ceramide to sphingosine. While sphingosine is 
considered like ceramide to be an apoptotic signaling molecule, it is also the necessary substrate for 
SK1 and the production of S1P. Thus sphingosine is an important intermediary, signaling for 
apoptosis while being readily available to be converted to a mitogenic signaling molecule. In fact, a 
study examining the role of ceramide in apoptosis found that overexpression of acid ceramidase 
protected cells from TNF-α-induced apoptosis, demonstrating the ceramidase expression may help 
shift the balance between intracellular ceramide and S1P levels towards cell survival (Strelow et al., 
2000).  
LC-MS analysis of sphingosine revealed that there is a trend toward upregulation of sphingosine in 
obese tissue, although the results do not differ significantly. Though sphingosine is a bioactive lipid 
itself, capable of apoptotic signals, it can be converted back to ceramide via ceramide synthase, or as 
previously mentioned, it can be phosphorylated to S1P by SK1. 
In contrast to SMase and ceramidase, SK1 expression was found to be downregulated in obese 
liver, by approximately 60%.  SK1 phosphorylates sphingosine to produce S1P, an important 




observed just below the 43 kDa mark in obese liver tissue. This could be demonstrating cross-
reactivity of a non-specific antibody with other proteins, as three other bands of various sizes were 
observed in western blotting with polyclonal anti-SK1 in liver tissue. For further SK1 analysis, a 
highly purified antibody is recommended to yield cleaner results. The decreased expression of SK1 in 
steatotic liver tissue may indicate lower levels of S1P being produced, and this further verifies the 
idea that in hepatic steatotic tissue there is a shift toward apoptosis, induced by the change in balance 
between sphingolipid signaling enzymes.  
LC-MS analysis of S1P showed that S1P levels were below detection level, meaning the levels of 
S1P for most samples were below 0.1 pmole/mg protein. S1P is normally at very low levels in vivo. 
Sphingosine-1- phosphatase can remove the phosphate, regenerating sphingosine or sphingosine-1-
phosphate lyase can act to irreversibly degrade S1P. Together, these two enzymes control S1P levels. 
A study comparing S1P levels in various rat tissues found that S1P is the lowest in the liver (Yatomi, 
1997) and this can be attributed to high levels of sphingosine-phosphate lyase (Veldhoven and 
Mannaerts, 1991). The low levels of S1P will increase only when SK1 is upregulated, induced by a 
diverse number of growth stimuli, including PDGF (Olivera et al., 1999; Olivera and Spiegel, 1993). 
Since it is clear in obese liver tissue that SK1 is downregulated, S1P levels would remain at a very 
low level.   
 
 Apoptotic Proteins in Liver Tissue 
This portion of the study was carried out to assess representative apoptotic proteins that are known to 
be affected by the sphingolipid pathway. A rise in ceramide levels will mediate apoptosis through 
PP2a. PP2a can activate pro-apoptotic Bax through dephosphorylation, leading to membrane 
permeation and subsequent cytochrome c release and apoptosis (Xin et al., 2006). Furthermore, 
ceramide has been implicated in the downregulation of anti-apoptotic Bcl-2. Bcl-2 binds to Bax and 
prevents Bax from initiating apoptosis at the mitochondrial membrane. PP2a may also play a role in 
ceramide induction of Bcl-2. PP2a activated by ceramide can dephosphorylate Bcl-2, rendering it 
inactive as an anti-apoptotic protein (Ruvolo et al., 1999).  
Analysis of Bax and Bcl-2 proteins by western blot showed that both are altered in obese liver 




level, consistent with the tendency of Bax to form dimers (Gross et al., 1998). Densitometric analysis 
of the 21kDa bands showed that Bax is upregulated in obese tissue by approximately 100% (Fig.11). 
Analysis of Bcl-2 found that Bcl-2 protein expression is approximately 75% lower in obese tissue 
(Fig.10). The altered levels of these two proteins in liver tissue suggest an increase in pro-apoptotic 
signals in obese liver tissue and is consistent with the diseased state of the steatotic liver tissue. 
Hepatocyte apoptosis is closely associated with steatosis. Increased expression of death receptors in 
obese livers sensitizes these cells to pro-apoptotic stimuli, thereby triggering excessive hepatocyte 
apoptosis and inflammation (Canbay et al., 2005). The altered levels of Bcl-2 and Bax observed in 
this portion of the study support the notion that steatotic liver is primed for apoptosis (Canbay et al., 
2005). It is possible that the altered sphingolipid signaling pathway is closely linked to the observed 
upregulation of Bax and downregulation of Bcl-2. As there are many other proteins involved in 
mediating apoptosis, further investigation is required to assess the role of these proteins in triggering 
cell death in steatotic liver. Furthermore, ceramide is not the only factor regulating the Bcl-2 family 
of proteins, so it cannot be assumed that these enzymes depend solely on the sphingolipid pathway. 
However, this study demonstrates that downstream effector proteins of the sphingolipid signaling 
pathway are altered in obese rats leading to the proposal that sphingolipid pathway and Bcl-2 proteins 
play a role in the pathogenesis of hepatic steatosis.  
 Summary of the Sphingolipid Pathway in Liver Tissue 
Sphingolipids are important molecules mediating apoptotic and mitogenic cellular responses. The 
dynamic balance between apoptotic ceramide and sphingosine and anti-apoptotic S1P and C1P will 
determine the proliferative or apoptotic fate of the cells (Reviewed in Chalfant and Spiegel, 2005; 
Ohanian and Ohanian, 2005). As these molecules are inter-convertible, the enzymes responsible for 
the catabolism and metabolism of these signalers are also important. Significant differences in 





Figure 44: Summary of sphingolipid signaling changes in obese liver tissue 
Arrows depict the observed trends of the sphingolipid enzymes and metabolites in obese liver tissue;  * depicts 
significant changes observed  (t-test, P<0.05); note that significant changes between SM and ceramide species 
observed are not depicted in this figure. 
 
Obese liver tissue differs significantly from lean liver tissue in its SM and ceramide composition, 
highlighting a shift in the fatty acid tail length in obese liver sphingolipids. The tail length of 
sphingolipids may have important biological implications in sphingolipid signaling, thus this is an 
area of much needed research. Overall the results demonstrate that in obese steatotic liver tissue, SM 
and C1P were present at lower levels, while ceramide was present at a higher level. Also, ceramidase 
protein expression was significantly higher, while SK1 expression was significantly lower. The 
changes in the levels of these enzymes in obese tissue suggest that the sphingolipid pathway is altered 
in obese animals.  
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The overall trend in the pathway appears to be shifting the balance in sphingolipid molecules away 
from survival signals (S1P and C1P) and toward stronger apoptotic (ceramide) signals. Expression 
levels of Bax and Bcl-2, showing upregulation and downregulation, respectively, also supports this 
shift toward apoptosis. The alteration of these two downstream proteins that can be regulated by 
ceramide levels suggest that the sphingolipid pathway and apoptotic proteins are working together to 
increase apoptotic sensitivity in the obese liver. The altered sphingolipid pathway in an obese state 
thus may be contributing to the pathogenesis of hepatic steatosis. Taken together, the results of this 
study suggest that the steatotic liver is more sensitive to apoptosis (Canbay et al., 2005), while future 
studies may help clarify the mode of action of sphingolipids in the pathogenesis of hepatic steatosis.  
4.2 Sphingolipid Signaling in Colon Tissue 
The colon is an organ which is highly proliferative with a constant turnover of cells. It is sensitive to 
cancer development and colon cancer is one of the leading types of cancer worldwide. 
Epidemiological data suggests that obesity is a risk factor for colon cancer. The Zucker obese rat 
model used in this study has proven to be more sensitive to carcinogen-induced colon cancer than its 
lean counterpart (Weber et al., 2000). This study was carried out to examine if the proinflammatory 
phenotype of the obese animal model may activate and alter the sphingolipid pathway prior to any 
disease development.  
Signal transduction of the pathway may begin with activation of SMase, hydrolyzing SM to ceramide. 
Enzyme activity analysis of SMase shows a trend toward higher SMase activity in the obese colon. In 
all repetitions of the assay, SMase activity was higher in the obese tissue compared to the lean tissue, 
although the differences were not statistically significant. LC-MS analysis of SM showed that there 
are no significant differences between SM levels in obese and lean colon. This indicates that the same 
level of substrate is available for SMase in both obese and lean tissue. Furthermore, no differences 
were observed when various species of SM were compared, showing that the total SM levels in each 
group are composed of relatively the same species (Fig.29).  
Analysis of the SMase metabolite, ceramide, showed also that although total levels were slightly 
higher in obese colon tissue, the difference was not statistically significant. However, when individual 
species were compared between groups, one particular species was significantly upregulated. C24:1-
ceramide was found to be higher in obese colon tissue (Fig.30). This particular species was also 
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upregulated in obese liver, indicating that this species of ceramide is more likely to be produced in 
obese tissue, either by SMase hydrolysis of C24:1-SM or by de novo synthesis. Although changes in 
total ceramide levels between groups were not seen, it must be noted that ceramide can be converted 
to less potent metabolites through glycosylation (to glycosylceramides), acetylation (to 
acylceramides) or to sphingosine via the action of ceramidase. Alternatively, ceramide can be 
phosphorylated by ceramide kinase to produce C1P.  
C1P signaling opposes ceramide signaling and functions to protect cells from apoptosis. LC-MS 
analysis shows that total levels of C1P were lower in obese tissue (Fig.33). Only two species of C1P, 
C16- and C18-ceramide, were detectable in colon tissue, and of these, C18-cermide species differed 
significantly between groups (Fig.32). The lower levels of C1P in obese tissue suggest that ceramide 
is not being shunted toward C1P in the sphingolipid pathway and that there is less of a survival signal 
present in obese tissue from this metabolite.  
To examine another route for ceramide in the signaling pathway, western blot analysis was 
performed to examine ceramidase protein expression. Acid-ceramidase antibody reacted with proteins 
40kDa in size, indicating that ceramidase is present as a mature beta subunit in colon tissue. 
Quantification of the western blot showed that this enzyme is significantly upregulated by 
approximately 50% in obese colon (Fig.25). Known inducers of ceramidase include PDGF and IGF-1 
(Suzuki et al., 2004). Overexpression of this enzyme has been shown to protect cells from stress-
induced apoptosis, most likely by helping prevent ceramide accumulation and push the pathway 
toward S1P production (Strelow et al., 2000). The observed upregulation of ceramidase in obese 
colon tissue suggests that more of this enzyme is present to convert ceramide to sphingosine, and this 
may be a protective response to help prevent excess ceramide accumulation in the obese colon.  
The product of ceramidase, sphingosine, was quantified by LC-MS. This analysis showed that there 
are no differences between sphingosine levels in lean and obese colon tissue. Compared to ceramide, 
sphingosine is considered to be a less potent inducer of apoptosis. As there were no differences 
observed between groups, and sphingosine levels were relatively low compared to other 
sphingolipids, it is clear that sphingosine is not accumulating in colon cells. Sphingosine is an 
important metabolite in the sphingolipid pathway, as it is the substrate for S1P production. 




To assess the production of S1P from sphingosine in colon tissue, SK1 was analyzed by western 
blot. SK1 was found to be significantly lower in obese tissue, by approximately 50%. As SK1 is 
necessary in the phosphorylation of sphingosine, it is clear that less enzyme is available in obese 
colon tissue to produce S1P. Western blot does not take into account the activity of the enzyme. So 
even though there are lower levels of SK1, no definite conclusions can be made about how much S1P 
is being produced in each tissue type. Also, as in liver tissue, S1P levels were too low to be detected 
by the LC-MS method used in this study. As mentioned earlier, S1P is normally present at very low 
levels in cells, and S1P will only accumulate if SK1 is stimulated by inducers such as PGDF (Olivera 
et al, 1999; Olivera and Spiegel, 1993). S1P is irreversibly degraded by S1P-lyase or is 
dephosphorylated by sphingosine-1-phosphatase. These two enzymes are active in vivo to keep S1P 
consistently at low levels, unless SK1 is induced. The downregulation of SK1 in obese colon tissue 




 Apoptotic Proteins in Colon Tissue 
Bcl-2 and Bax were analyzed in order to assess if these proteins were altered in the colon of obese 
rats. As these proteins are downstream of the sphingolipid signaling pathway, it was valuable to see if 
any alterations occurred at this level in the apoptotic signaling process. Western blot analysis of Bax 
showed the protein at a band size of 42kDa, consistent with the tendency of the 21kDa Bax to form 
homodimers (Gross et al., 1998). Bax forms strong dimers and even though western blotting was 
carried out under denaturing conditions, antibody specifications indicated that it is common for this 
antibody to react with the dimerized form of the protein. Densitometric analysis showed that Bax is 
100% upregulated in obese colon compared to lean. Bax induces apoptosis by permeating the 
mitochondrial membrane, allowing cytochrome c release, and subsequent apoptosis through 
activation of caspases. This upregulation of Bax suggests that the tissue may be primed for apoptosis. 
Bax is normally located in the cytosol and upon activation migrates to the mitochondrial membrane 
and stimulates the apoptotic process. The higher level of Bax along with altered sphingolipid pathway 




Western blot using Bcl-2 antibody showed bands at a size of 60kDa in all repetitions of this blot in 
colon tissue. This is twice the predicted band size for Bcl-2 as it is a 26kDa protein (Chao et al., 
1998). Bcl-2 commonly forms dimers with other Bcl-2 family proteins, and is also capable of forming 
homodimers and oligodimers. Both monomeric and dimerized Bcl-2 are capable of interacting with 
activated Bax protein (Zhang et al., 2004). However; competition analysis showed that the formation 
of a Bax/Bcl-2 heterodimer is favored and this interaction inhibits Bcl-2 homodimerization (Zhang et 
al., 2004). It is interesting then that Bcl-2 appears to be present as homodimers in tissue that also has 
upregulated Bax levels. However, it cannot be said with certainty that the 60kDa bands observed do 
represent Bcl-2 homodimers or any other Bcl-2 dimer, as western blotting was carried out under 
denaturing conditions. The bands could also be demonstrating cross-reactivity of this antibody with 
another protein and remains to be characterized. Recent information on the polyclonal antibody used 
does reveal that the antibody has demonstrated non-specific binding at 37 and 45kDa and has been 
suggested to react to other Bcl-2 family members. Perhaps this may explain the unpredicted band size 
observed in our analysis (Abcam, 2007).  All that can be concluded from this portion of the study is 
that Bax is significantly upregulated in obese colon tissue, while further analysis is required to 
confirm changes in Bcl-2 levels.  
 Summary of the Sphingolipid Pathway in Colon Tissue 
Bioactive sphingolipids are important mediators of cell proliferation, differentiation, and programmed 
cell death. In the colon, cell turnover occurs at a rapid pace to maintain healthy colonic epithelium. 
An alteration in the sphingolipid pathway has been implicated in the etiology of colon cancer and 
studies examining sphingolipid enzymes and metabolites in colonic tumor tissue have exploded in 
recent years (Reviewed by Segui et al., 2006). Investigation of the pathway in obese colon tissue 






Figure 45: Summary of sphingolipid signaling changes in obese colon tissue 
Arrows depict the observed trends of the sphingolipid enzymes and metabolites in obese colon tissue; * depicts 
changes that were statistically significant (t-test, P<0.05); note that significant changes between SM and 
ceramide species are not depicted in this figure. 
 
The obese genotype has a significant effect on sphingolipids and their enzymes. Most notably 
altered in obese colon tissue were ceramidase, SK1 and C1P levels. Unlike the liver, there were no 
considerable shifts in ceramide and SM species compositions between groups, and overall there were 
fewer notable differences between obese and lean groups in colon tissue compared to liver tissue. The 
overall trends observed in the sphingolipid pathway remain consistent in both tissue types; 
ceramidase is upregulated while sphingosine kinase is downregulated. Again, since this study did not 
quantify the activity levels of the enzymes, it can only be noted that the available levels of this 
enzymes are altered in obese tissues. C1P levels are also downregulated in both tissue types, 
demonstrating that less of this survival signaling molecule is available in obese tissue. This, in 
concurrence with the lowered SK1 levels may suggest a shift toward apoptotic signaling. However, 
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without any noticeable differences in ceramide levels in colon tissue, this is merely a speculation and 
remains to be validated.  The pro-apoptotic Bax demonstrated significant upregulation in obese colon 
tissue, providing further evidence that obese colon tissue is more prone to apoptosis, and that the 
sphingolipid metabolites may work in concert with apoptotic proteins.  While the significance of the 
alterations in the sphingolipid pathway cannot be explicitly portrayed in this study, the important 
finding is that the sphingolipid pathway is altered in an obese state and this may have valuable 
implications in the etiology of colon cancer.  
Numerous studies have looked at the sphingolipid pathway in colon tumor tissue. Findings 
include a significant reduction in ceramide levels in colon carcinomas compared to healthy mucosa, 
and an overexpression of SK1 in malignant colon cells (Selzner et al., 2001; Kawamori et al., 2006). 
Ceramidase enzyme may also have an important role in cancer development, as ceramidase inhibition 
resulted in ceramide accumulation and induction of cell death in colonic tumor cells (Selzner et al., 
2001). These findings implicate low ceramide levels and dysfunctions in the sphingolipid pathway in 
the pathogenesis of colon carcinogenesis. It has previously been established that Zucker obese rats are 
more sensitive to azoxymethane-induced colon carcinoma (Weber et al., 2000). If in fact obese colon 
tissue has a shifted apoptotic balance due to its aberrant sphingolipid pathway, it is quite possible that 
this shift exposes a link between obesity and colon cancer development. Whether this shift creates an 
environment more susceptible to apoptosis or an environment more conducive to cell survival 
remains to be determined. However, it is clear that induced tumors are more likely to develop in the 
environment of obese colon tissue compared to lean colon tissue. Thus a likely hypothesis is that 
altered sphingolipid pathway in obese colon tissue contributes to an environment more sensitive to 
colon carcinogenesis. This, along with the knowledge that malignant cells have altered sphingolipid 
profiles compared to normal mucosa, provide strong value to further investigate the sphingolipid 
pathway and apoptotic state of obese colon tissue in the pathogenesis of colon carcinoma.  
 
4.3 Tissue Specific Differences between Liver and Colon Tissue 
Liver and colon have completely different functions and thus differ histologically. In comparing 
sphingomyelinase activity and sphingolipid levels between liver and colon tissue, it is clear that there 
are tissue specific differences in the sphingolipid pathway. Both isoforms of SMase, neutral and 
acidic, were found to be upregulated in colon tissue compared to liver tissue (Figs. 34 and 35). 
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Interestingly, SMase substrate, SM, is also at higher levels in colon tissue. This indicates that per 
milligram of colon tissue, there is more SM present for hydrolysis by SMase. Comparison of 
ceramide levels in colon and liver also show that ceramide is upregulated in colon tissue. This implies 
that the active SMase is resulting in greater ceramide production in colon tissue. Ceramide can also be 
produced by de novo synthesis; however, the upregulated SM and higher SMase activity in colon 
suggest that SM hydrolysis likely accounts for at least part of the high ceramide production seen in 
this tissue.   
Closer examination of ceramide and SM shows that there is a shift in species composition for both 
sphingolipids between tissue types (Figs. 38 and 41). Varying carbon chain length and number of 
double bonds in the fatty acid chain of ceramide and SM may have important biological implications. 
However, as little is known about the biological importance of varying fatty acid chain length in these 
sphingolipids this is an excellent area for future research. 
Other comparisons of the pathway between tissue types show a trend toward lower sphingosine in 
colon compared to liver, as well as significantly lower C1P levels. The downregulation in this portion 
of the pathway demonstrate that the colon tissue may be accumulating ceramide and producing less of 
a proliferative signal in the form of C1P. Taken together, the results of this portion of the study 
indicate that colon tissue is subjected to stronger apoptotic signals than liver tissue, as suggested by 
the higher SMase activity, higher ceramide, and lower C1P levels.  These tissue-specific differences 
may be accounted for by the fact that the colon has relatively higher cell turnover, therefore requiring 
cell death signals (Deschner et al., 1987). In both animals and humans, apoptosis occurs in colonic 
crypts and villi unrelated to a known stimulus and may function to regulate the number of colonic 
cells (Johnson, 2006).  As ceramide can mediate programmed cell death, there may be more of a 
requirement for production of this sphingolipid in colon tissue than in liver tissue. Thus the 
differences observed in SMase activity and ceramide levels in liver and colon may be indicative of 




4.4 Conclusions and Future Directions 
The sphingolipid pathway can be activated in various situations of cellular stress. To establish 
whether inflammation and reactive oxygen species that are associated with a state of obesity could 
alter the sphingolipid signaling pathway, key enzymes and bioactive sphingolipids were assessed in 
obese Zucker rats. As obese livers demonstrate hepatic steatosis, and obese colons are more sensitive 
to colon cancer, these two tissue types were selected for analysis. The results of this study 
demonstrate an obese genotype can significantly alter elements of the sphingolipid signaling pathway 
in both tissue types.  
Key findings include the following: 
• Higher expression of ceramidase and lower expression of SK1, as well as a trend toward 
higher SMase activity in obese steatotic liver compared to lean liver.  
• Lower C1P levels and a trend toward a higher ceramide levels in obese liver. 
•  An increase in Bax levels and decrease in Bcl-2 levels in the obese liver. Taken together 
with sphingolipid pathway analysis, these results show for the first time a trend toward 
increased sphingolipid apoptotic signaling in obese liver tissue and are consistent with the 
pathological state of steatotic liver. 
• A shift in SM and ceramide species composition in obese liver compared to lean liver. 
Alteration in the carbon tail chain length of fatty acids in sphingolipids may have important 
biological implications, thus this is an area for future research.  
• An upregulation of ceramidase and downregulation of SK1 in obese colonic tissue, same as 
in liver tissue.  
• Lower C1P levels in obese colon tissue. 
• An increase in Bax protein levels in obese colonic tissue. Bcl-2 results were inconclusive.  
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• An upregulation of SMase activity and an upregulation of ceramide and SM levels in colon 
tissue compared to liver. These results indicate tissue-specific differences in the 
sphingolipid pathway. 
In conclusion, an obese genotype does affect the sphingolipid pathway in both liver and colon 
tissue and this may have important implications in the pathogenesis of both hepatic steatosis and 
colon cancer. 
Future studies must be designed using larger sample size to further explore the differences in 
sphingolipid signaling in an obese state. An expansion on the sphingolipid enzymes and molecules 
examined would also help elucidate differences. Furthermore, an investigation into sphingolipid 
species differences is necessary to determine whether or not variations in fatty acid tail composition 
of ceramide and sphingomyelin have a structural or functional effect. To further investigate the role 
of sphingolipid signaling in the pathogenesis of colon cancer in a state of obesity, it would be prudent 
to analyze sphingolipid signaling during the growth of the colonic tumor in obese and lean animal 
models.  
This is a novel and exciting area of research. Further investigation and analysis of the sphingolipid 
pathway in obese liver and colon, as well as a deeper understanding of the activation and regulation 
of this pathway should elucidate the effect of obesity and the role of sphingolipid signaling in the 
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Apaf-1 apoptotic protease activating factor 1 
ATP adenosine triphosphate 
Bax Bcl-2 associated X protein 
Bcl-2 B cell lymphoma-2 
C1P ceramide-1-phosphate 
CAPP ceramide-activated protein phosphatase 
CerK ceramide kinase 
DNA deoxyribonucleic acid 
Edg receptor endothelial differentiation gene receptor 
HPLC high-performance liquid chromatography 
JNK Jun kinase 
IGF insulin-like growth factor  
IL-1β interleukin-1 beta 
LC-MS liquid chromatography-mass spectroscopy 
MAPK mitogen-activated protein kinase 
MLK mixed lineage kinase 
MS mass spectroscopy 
NAFL nonalcoholic fatty liver 
NASH nonalcoholic steatohepatitis 
PGDF platelet-derived growth factor 
PKB protein kinase B 
PKC protein kinase C 
PP1 protein phosphatase 1 
PP2a protein phosphatase 2a 
ROS reactive oxygen species 
S1P sphingosine-1-phosphate 
SAPK stress-activated protein kinase 





SK sphingosine kinase 
TNF-α tumor necrosis factor alpha 
VLDL very low density lipoproteins 




Appendix B                                                                       
Additional Liver and Colon Result Figures 
 























Figure B1: Sphingosine levels in lean and obese liver tissue 
Sphingosine levels are shown in pmole/mg protein ± s.e.m. N=5 per group. Sphingosines were quantified by 
HPLC-MS. 17C-sphingosine was used as an internal standard.  After sphingolipid extraction, samples 































Figure B2: Total sphingomyelin content in lean and obese colon tissue 
SM levels are shown in pmole/mg protein ± s.e.m. N=5 per group. SMs were quantified by HPLC-MS. 18C17-
SM was used as an internal standard.  After sphingolipid extraction, samples containing 1mg of protein were 


































Figure B3: Total ceramide content in lean and obese colon tissue  
Ceramide levels are shown in pmole/mg protein ± s.e.m. N=5 per group. Ceramides were quantified by HPLC-
MS. 17C16-ceramide was used as an internal standard.  After sphingolipid extraction, samples containing 1mg 





















Figure B4: Sphingosine levels in lean and obese colon 
Sphingosine levels are shown in pmole/mg protein ± s.e.m. N=5 per group. Sphingosines were quantified by 
HPLC-MS. 17C-sphingosine was used as an internal standard.  After sphingolipid extraction, samples 



























Figure B5: Total sphingosine content in lean liver and colon 
Sphingosine levels are shown in pmole/mg protein ± s.e.m. N=5 per group. Sphingosines were quantified by 
HPLC-MS. 17C-sphingosine was used as an internal standard.  After sphingolipid extraction, samples 
containing 1mg of protein were analyzed using TSQ 7000 LC/MS system.  
 
























Figure B6: Total sphingosine content in obese liver and colon 
Sphingosine levels are shown in pmole/mg protein ± s.e.m. N=5 per group. Sphingosines were quantified by 
HPLC-MS. 17C-sphingosine was used as an internal standard.  After sphingolipid extraction, samples 







Appendix C                                                                       
Sphingolipid Data Tables 
The following tables consist of the raw data quantification values for ceramide, SM, C1P, sphingosine 
and S1P in obese liver and colon.  
 
 





























LC 1 L 10.7 0.4 238.8 13.8 22.2 1.8 1.9 96.9 20.2 711.3 223.0 0.2 1.7 
LC 2 L 13.4 0.7 468.9 23.4 22.4 2.1 2.1 75.0 19.6 657.6 241.3 6.1 7.6 
LC 3 L 8.4 0.3 184.4 14.2 14.0 1.2 0.7 46.8 10.2 445.6 253.5 4.5 2.8 
LC 4 L 11.0 0.3 116.0 13.8 13.0 1.8 0.6 59.0 8.3 429.3 320.9 4.1 2.7 
LC 5 L 9.6 0.2 232.5 15.8 14.7 1.4 1.0 50.4 12.3 439.7 261.6 3.6 4.3 
OC 1 L 7.0 0.4 69.7 15.2 15.9 1.7 5.3 98.5 10.0 492.5 450.7 6.3 2.7 
OC 2 L 11.9 0.4 142.3 40.6 27.8 2.1 13.0 105.4 20.2 489.3 499.2 4.3 5.1 
OC 3 L 13.8 1.4 103.8 53.8 30.0 2.4 6.7 143.6 20.5 516.9 723.2 2.4 1.9 
OC 4 L 13.4 1.3 86.7 59.1 31.7 2.4 7.5 114.6 21.7 410.6 554.1 2.9 2.1 
OC 5 L 8.2 0.6 98.1 48.2 27.4 1.9 7.4 126.6 17.6 519.9 583.9 3.4 1.9 
LC 1 Col 71.1 1.4 651.2 191.0 142.3 66.4 1.0 51.4 19.3 173.8 262.7 2.1 1.4 
LC 2 Col 59.5 2.1 691.0 145.3 140.6 82.4 2.5 51.2 15.4 128.7 229.6 1.8 1.0 
LC 3 Col 87.1 7.6 646.0 214.3 158.9 119.1 0.6 71.6 17.0 176.7 322.8 5.1 1.9 
LC 4 Col 114.2 3.8 537.9 245.7 113.3 80.4 0.6 50.7 18.3 152.5 287.0 1.6 2.2 
LC 5 Col 120.4 5.7 454.7 377.7 172.2 110.1 0.5 70.3 15.2 192.9 393.0 2.9 2.7 
OC 1 Col 105.0 5.0 860.6 273.7 173.5 76.8 1.2 66.7 19.9 192.2 463.1 3.2 3.0 
OC 2 Col 102.9 2.3 1022 274.8 226.8 104.5 0.8 80.5 22.1 158.8 535.8 2.0 1.6 
OC 3 Col 94.7 7.3 647.8 226.5 145.2 96.7 0.5 63.2 23.5 115.9 364.9 1.5 1.3 
OC 4 Col 50.9 3.1 559.2 94.8 82.5 42.8 2.2 52.9 7.6 145.3 348.9 1.8 1.8 
OC 5 Col 82.3 3.5 586.6 197.3 75.4 51.4 0.6 48.8 14.3 106.6 350.6 1.1 1.9 
              
bCer = ceramide; LC*L = lean control liver sample; OC*L = obese control liver sample; LC*Col = lean control 







     Table B2: SM Concentration (pmole/mg pro)c     
Sample 

























LC 1 L 2.7 555.0 518.0 5.7 195.8 6.4 1028.2 120.1 3359.2 1632.6 56.8 25.6 
LC 2 L 3.3 690.0 535.0 4.6 202.6 6.6 925.3 140.0 3281.6 1516.9 78.2 50.9 
LC 3 L 2.8 760.0 462.0 4.0 175.7 5.8 825.0 111.4 3149.3 1619.9 57.1 40.3 
LC 4 L 2.6 832.0 524.0 4.9 187.6 7.0 945.6 122.6 3045.8 1602.2 68.6 41.6 
LC 5 L 1.9 710.0 422.0 4.1 132.6 5.2 803.5 87.7 3324.4 1445.2 52.9 37.1 
OC 1 L 42.5 3630.0 1710.0 78.8 784.6 95.9 507.7 97.6 713.5 1105.7 8.6 7.4 
OC 2 L 7.6 1470.0 680.0 6.9 158.8 6.8 658.2 90.0 1656.4 1718.8 13.9 18.5 
OC 3 L 7.1 1590.0 684.0 6.3 155.2 6.0 691.0 76.4 1571.8 1601.1 10.2 11.6 
OC 4 L 6.2 1230.0 782.0 7.0 185.9 6.5 695.8 94.2 1539.8 1599.8 10.2 13.2 
OC 5 L 6.4 1360.0 551.0 5.1 142.3 4.7 674.1 65.3 1698.6 1424.6 12.1 9.8 
LC 1 Col 0.0 4760.0 2240.0 131.0 922.3 143.3 578.3 137.9 700.6 1330.1 7.0 7.5 
LC 2 Col 4.3 1200.0 393.0 4.3 116.6 5.0 614.1 68.0 1673.3 1293.1 13.1 10.9 
LC 3 Col 67.3 6540.0 2030.0 122.0 896.6 128.3 607.6 128.7 913.5 1277.1 10.4 8.8 
LC 4 Col 32.7 5240.0 2860.0 192.0 1126.1 195.0 706.5 177.0 885.7 1697.8 8.7 9.3 
LC 5 Col 37.8 5560.0 2680.0 210.0 1034.2 176.5 711.2 160.3 982.6 1691.6 7.0 8.1 
OC 1 Col 36.9 5610.0 2430.0 147.0 938.4 139.8 576.3 132.5 640.6 1837.7 5.1 7.1 
OC 2 Col 30.3 6080.0 3610.0 182.0 1471.0 180.6 863.4 217.8 1131.1 3003.0 8.4 12.8 
OC 3 Col 32.1 4080.0 2550.0 132.0 1034.2 144.3 633.2 160.3 771.2 1961.8 5.7 8.7 
OC 4 Col 39.0 4310.0 1850.0 74.6 793.7 92.0 537.3 113.1 807.8 1820.4 7.3 8.6 
OC 5 Col 31.5 5570.0 2310.0 120.0 816.6 116.2 498.9 112.3 646.6 1603.3 6.2 7.5 
 
c LC*L = lean control liver sample; OC*L = obese control liver sample; LC*Col = lean control colon sample; 











    Table B3: C1P  Concentration (pmole/mg pro)d
Sample ID C14-C1P C16-C1P C18-C1P C18:1-C1P C20-C1P C22-C1P C24-C1P C24:1-C1P C26-C1P C26:1-C1P 
LC 1 L BDL 51.3 664.7 56.1 2.5 BDL 0.1 BDL 0.2 0.3 
LC 2 L BDL 92.3 988.5 28.3 2.0 BDL 0.1 BDL BDL 0.1 
LC 3 L BDL 55.7 917.0 12.3 BDL BDL 0.1 BDL BDL BDL 
LC 4 L BDL 62.3 956.4 14.1 2.7 BDL 0.1 BDL 0.2 0.1 
LC 5 L BDL 49.9 725.2 7.4 BDL BDL BDL BDL BDL BDL 
OC 1 L BDL 62.0 429.3 1.4 BDL BDL BDL BDL BDL BDL 
OC 2 L BDL 55.7 251.0 1.4 1.6 BDL 0.0 BDL BDL BDL 
OC 3 L BDL 28.3 569.3 1.2 1.1 BDL BDL BDL BDL BDL 
OC 4 L BDL 33.8 301.5 0.6 0.1 BDL BDL BDL BDL BDL 
OC 5 L BDL 46.1 663.7 1.3 0.5 0.2 BDL BDL BDL BDL 
LC 1 Col BDL 57.9 179.1 0.6 0.1 BDL BDL BDL BDL BDL 
LC 2 Col BDL 52.4 742.5 BDL 0.8 BDL BDL BDL 0.0 BDL 
LC 3 Col BDL 51.7 685.7 BDL 0.5 BDL BDL BDL BDL BDL 
LC 4 Col BDL 72.0 658.5 0.8 BDL BDL BDL BDL BDL 0.1 
LC 5 Col BDL 50.2 660.3 0.5 0.7 BDL BDL BDL BDL 0.1 
OC 1 Col BDL 46.4 126.6 0.1 BDL BDL BDL BDL BDL BDL 
OC 2 Col BDL 61.0 301.6 0.3 0.0 BDL 0.3 BDL BDL BDL 
OC 3 Col BDL 50.1 198.1 0.1 BDL 0.0 0.0 BDL BDL BDL 
OC 4 Col BDL 37.7 105.6 BDL 0.1 BDL 0.0 BDL 0.0 BDL 
OC 5 Col BDL 61.7 241.1 0.0 BDL BDL BDL BDL BDL BDL 
 
d BDL= below detection level; LC*L = lean control liver sample; OC*L = obese control liver sample; 







      Table C4: Sphingosine and S1Pe




LC 1 L 11.9 BDL 
LC 2 L 11.4 BDL 
LC 3 L 11.0 BDL 
LC 4 L 9.5 0.7 
LC 5 L 8.4 BDL 
OC 1 L 7.6 BDL 
OC 2 L 26.4 BDL 
OC 3 L 17.0 0.9 
OC 4 L 7.7 BDL 
OC 5 L 8.3 1.2 
LC 1 Col 4.3 BDL 
LC 2 Col 3.6 BDL 
LC 3 Col 14.0 1.9 
LC 4 Col 5.4 BDL 
LC 5 Col 5.2 BDL 
OC 1 Col 4.6 BDL 
OC 2 Col 11.8 BDL 
OC 3 Col 10.5 8.6 
OC 4 Col 6.3 BDL 
OC 5 Col 4.5 4.4 
e Sph = sphingosine; BDL = below detection level; LC*L = lean control liver sample; OC*L = obese control 
liver sample; LC*Col = lean control colon sample; OC*Col = obese control colon sample. 
Appendix D                                                                      
Animal Diet Composition 
Table D1: Diet Composition (g/Kg) for Lean and Obese Zucker Rats: 
 
 102  
